

(19) **DANMARK**

(10) **DK/EP 3606926 T3**



Patent- og
Varemærkestyrelsen

(12) Oversættelse af
europæisk patentskrift

-
- (51) Int.Cl.: **C 07 D 487/04 (2006.01)** **A 61 K 31/437 (2006.01)** **A 61 P 31/12 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2021-07-05**
- (80) Dato for Den Europæiske Patentmyndigheds
bekendtgørelse om meddelelse af patentet: **2021-05-26**
- (86) Europæisk ansøgning nr.: **18716212.8**
- (86) Europæisk indleveringsdag: **2018-04-04**
- (87) Den europæiske ansøgnings publiceringsdag: **2020-02-12**
- (86) International ansøgning nr.: **EP2018058522**
- (87) Internationalt publikationsnr.: **WO2018185120**
- (30) Prioritet: **2017-04-05 EP 17165082**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV
MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **CUROVIR AB, P.O. Box 716, 391 27 Kalmar, Sverige**
- (72) Opfinder: **WESTMAN, Jacob, Jonsund Blomsberg 109, 744 97 Järlåsa, Sverige**
- (74) Fuldmægtig i Danmark: **Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, Danmark**
- (54) Benævnelse: **HETEROAROMATISKE FORBINDELSER ANVENDELIGE I TERAPI**
- (56) Fremdragne publikationer:
WO-A1-2016/206999
WO-A2-2015/110491

DESCRIPTION

FIELD OF THE INVENTION

[0001] The present invention relates generally to novel compounds having usefulness in therapy, in particular in the treatment of viral conditions, more particularly viral conditions caused by picornaviruses, e.g. enteroviruses. The present invention also relates to novel compounds having usefulness for the treatment of diseases such as meningitis, hand-foot and mouth disease, herpangina, respiratory disease, encephalitis and myocarditis, but also including diabetes, cancer, neurodegenerative diseases such as Alzheimer's disease and amyotrophic lateral sclerosis.

BACKGROUND OF THE INVENTION

[0002] Pyrazolo[1,5-a]pyrimidine derivatives have been described as analgesics, benzodiazepine receptor antagonists, angiotensin II receptor antagonists, angiogenesis inhibitors, antiinflammatory agents, neuropeptide Y receptor antagonists, COX2-inhibitor and corticotrophin-releasing hormone receptor type 1 antagonists and as CHK1 inhibitors (e.g. Mayo et al (Adv. Synth. Catal. 2003, 345, 620-624; Tellew et al (Bioorg. Med. Chem. Lett. 2010, 20, 7259-7264); Chen et al (Bioorg. Med. Chem. Lett. 2004, 14, 3669-3673); Labroli et al (Bioorg. Med. Chem. Lett. 2011, 21, 471-474); Griffith et al (Bioorg. Med. Chem. Lett. 2011, 21, 2641-2645); Gilligan et al, (J. Med. Chem. 2009, 52, 3073-3083); He et al. (US Patent No. 6,313,124 B1); and Wren et al. (WO 2010/086040), Catalano et al (Tetrahedron Lett. 2015, 56, 6077-6079). The pyrazolo[1,5-a]pyrimidine scaffold has also been described in phosphatidylinositol 4-kinase (PI4K) inhibitors. Bianco et al (PLoS Pathogens, 2012, 8(3), 1-17) and LaMarche et al (Antimicrob. Agents and Chemother. 2012, 56(10), 5149-5156) have shown that PI4K is important for hepatitis C virus (HCV) replication and Yang et al (J. Biol. Chem. 2012, 287(11), 8547-8467) have shown the same for coronavirus. Gudmundsson et al (Bioorg. Med. Chem. Lett. 2009, 19, 5689-5692) have disclosed some 3-arylpyrazolo[1,5-a]pyrimidines with potent activity against herpes virus. Hwang et al (Bioorg. Med. Chem. Lett. 2012, 22, 7297-7301) have described 3-arylpyrazolo[1,5-a]pyrimidines as PI4K inhibitors that have anti-HCV effects. In WO 2015/110491 some further pyrazolo[1,5-a]pyrimidine derivatives are described as PI4KIII β inhibitors having an antiviral activity. Pyrazolo[1,5-a][1,3,5]triazine derivatives have been described as corticotropin-releasing factor receptor-1 (CRF1) antagonists which may be potential anxiolytic and antidepressant drugs (cf. for example, Gilligan et al (J. Med. Chem. 2009, 52, 3073-3083). Pexacerfont is a clinically tested pyrazolo[1,5-a] triazin-4-amine drug developed by Bristol-Myers Squibb, acting as a CRF-1 antagonist. The pyrazolo[1,5-a][1,3,5]triazine scaffold has also been described as present in cyclin-dependent kinase inhibitors (WO2013128029), casein kinase inhibitors and DYRK1A kinase inhibitors (WO2010103486) useful for treatment of various diseases. The scaffold has further been described as present in cannabinoid 1 receptor antagonists (J. Pharm. Exp. Ther. (2010), 335(1), 103-113). Pyrazolo[1,5-a] triazin-4-amines have been described as PI4K inhibitors with antiviral potency in

Mejdrova et al (J. Med. Chem., 2015, 58 (9), 3767-3793), and in Mejdrova et al (J. Med. Chem., 2017, 60 (1), 100-118). In WO2016206999 some further pyrazolo[1,5-a]triazine derivatives are described as PI4KIIIIP inhibitors having an antiviral activity.

[0003] Imidazo[1,2-b]pyridazine derivatives have been described as Mps1 kinase inhibitors (Kusakabe, J. Med. Chem. 2015, 58, 1760-1775). Similar scaffolds have been described as present in phosphatidylinositol 4-kinase (PI4K) inhibitors (McLeod et al (ACS Med. Chem. Lett. 2013, 4(7), 585-589) and van der Schaar et al (Antimicrobial Agents Chemother. 2013, 57(10), 4971-4981), and inhibitors of PI4K have been shown to be potent antivirals (Bianco et al, PLoS Pathogens, 2012, 8(3), 1-17; LaMarche et al, Antimicrob. Agents and Chemother. 2012, 56(10), 5149-5156; Décor et al, Bioorg. Med. Chem. Lett. 2013, 23, 3841-7).


[0004] Décor et al (Bioorg. Med. Chem. Lett. 2013, 23, 3841-7) have also shown that PI4K is important for enterovirus replication. However, they have also shown that PI4K inhibitors (non 3-arylpyrazolo[1,5-a]pyrimidines) and the 3-arylpyrazolo[1,5-a]pyrimidine 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(2-morpholinoethyl)pyrazolo[1,5-a]pyrimidin-7-amine (called T-00127-HEV1) when tested in-vivo induced mortality in mice, which raised doubts on the safety of inhibiting PI4K. Sala et al (Bioorg. Med. Chem. Lett. 2016, 26(11), 2706-12) have published several analogs based on the PI4KIII β inhibitor T-00127-HEV1. The authors made a number of analogs with modifications in the central rings of the compounds.


[0005] Autophagy is a process of homeostatic degradation in cells, used to create nutrients in times of stress and as a mechanism to recycle damaged organelles or microbes in the cytosol (Karanasios et al, 2016, Autophagy at the cell, tissue and organismal level (Springer)). Many pathogens interact with the host autophagic pathways and could impair the normal autophagy. Lai et al (Viruses, 2016, 8(32), 1-13) describe that viruses subvert the autophagy machinery to benefit the virus replication and exit from the host and that inhibition of PI4KIII β will have an effect on the autophagy processes and thus inhibit the virus replication. Sridhar et al (EMBO J. 2013,32, 324-339) describe PI4KIII β to be a key factor in autophagy and it is believed that many diseases are caused by or linked to impaired or abnormal autophagy, for example neurodegenerative and neuropsychiatric diseases, cancer, cardiac diseases, inflammatory diseases and diabetes (Polajnar et al J. Cell. Mol. Med. 2014, 9(18). 1705-1711; Levine et al, Cell, 2008, 132(1), 27-42; Barlow, et al, DNA Cell. Biol, 2015, 34(4), 252-260). Without being bound to any theory it is believed that compounds of the present invention also could be used for treatment of diseases caused by or linked to impaired or abnormal autophagy.

[0006] There remains a need for novel, therapeutically active compounds, e.g. antiviral agents.

SUMMARY OF THE INVENTION

[0007] A first aspect is a compound of formula (I)





or a pharmaceutically acceptable salt thereof, wherein

X is CH or N;

Y is N and Z is C; or Y is C and Z is N;

the 5-membered ring containing N, Y and Z is a heteroaromatic ring;

ring A is phenyl or 5- or 6-membered heteroaryl having one or more, e.g. one or two, heteroatoms independently selected from N, O and S;

m is 0, 1 or 2;

each R_1 is independently selected from halogen, C1-C6 alkyl, R_2O , $R_3S(O)_2$, $R_4S(O)_2N(R_5)$, $R_6R_7NC(O)$, $R_8C(O)N(R_9)$, $R_{10}C(O)$, $R_{11}R_{12}N$, and $R_{13}R_{14}NS(O)_2$, and

when m is 2, two R_1 attached to adjacent atoms of ring A, together with the atoms to which they are attached, may form a 5- or 6-membered heterocyclic or carbocyclic ring;

each one of R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} , R_{11} , R_{12} , and R_{13} is independently selected from H and C1-C6 alkyl;

R_{14} is selected from H, C1-C6 alkyl, $R_{15}C(O)$, and $R_{16}OC(O)$;

R_{15} and R_{16} are independently selected from H and C1-C6 alkyl; and

any alkyl is optionally substituted by one or more halogen.

[0008] A further aspect is a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use as an inhibitor of picornavirus replication.

[0009] A further aspect is a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use as an inhibitor of picornaviral cytopathogenic effects.

[0010] A further aspect is a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use as an inhibitor of phosphatidylinositol 4-kinase III β .

[0011] A further aspect is a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use to modulate autophagy.

[0012] A further aspect is a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in therapy.

[0013] A still further aspect is a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient.

[0014] A further aspect is a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of a viral infection.

[0015] A further aspect is a compound of formula (I), or a pharmaceutically acceptable salt thereof, capable of improving impaired or modulating abnormal autophagy in a cell, for use in the treatment of a disease as mentioned herein.

[0016] A further aspect is a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease linked to impaired or abnormal autophagy.

[0017] A further aspect is a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease linked to impaired autophagy.

[0018] A further aspect is a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease linked to abnormal autophagy.

[0019] By "abnormal autophagy" is meant e.g. autophagy that favours viral replication and release.

[0020] By "impaired autophagy" is meant a subnormally functioning autophagy in a cell.

[0021] A disease linked to impaired or abnormal autophagy that may be treated according to the invention e.g. may be selected from neurodegenerative and neuropsychiatric diseases, cancer, cardiac diseases, inflammatory diseases and diabetes, such as diseases mentioned herein.

[0022] A further aspect is a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of a non-enveloped single-stranded (+) RNA viral infection.

[0023] Still a further aspect is a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of pancreatitis, poliomyelitis, encephalitis, meningitis, sepsis, cancer, such as breast, prostate, ovarian and colorectal cancer, paralysis, cardiac diseases, such as myocarditis, diabetes, common cold, hand-foot-and-mouth disease, herpangina, pleurodynia, diarrhea, mucocutaneous lesions, respiratory illness, conjunctivitis, myositis, chronic fatigue syndrome, neuropsychiatric diseases, and neurodegenerative diseases such as multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, and Huntington's disease, or inflammatory conditions.

[0024] A further aspect is the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disorder or disease as mentioned herein.

[0025] A further aspect is a method for the treatment of a disorder or disease as mentioned herein by administration of a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a mammal in need thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

[0026]

Figure 1 is a bar chart showing the dose response of inhibition of Coxsackie B3 Nancy strain induced cytopathogenic effect by addition of 6 different compounds of the present invention, at two different concentration of the virus to the cells at infection.

Figure 2 is a graph showing the pharmacokinetic profile, expressed as ng/ml of compound of the invention in samples of blood extracted from rats at different time points after administration of 6 different compounds of the present invention at a dose of 50 mg/kg.

Figure 3 is a graph showing pancreatitis scoring in Coxsackie B3, Nancy strain infected SJL mice after treatment with different doses of Example 8. 0 = no abnormalities. 1 = slight inflammation and/or single cell foci in exocrine pancreas. 2 = moderate inflammation and/or several foci with necrosis in exocrine pancreas. 3 = severe inflammation and/or large areas of necrosis in exocrine pancreas.

Figure 4 is a graph showing the virus titer scoring in Coxsackie B3, Nancy strain infected SJL mice after treatment with different doses of Example 8, based on immunohistochemistry using the Dako 5-D8/1 monoclonal mouse antibody. A score 4 indicates the highest virus titer and a score 0 indicates no infection

Figure 5 is a graph showing the Ct values from PCR detection of virus titer in Coxsackie B3, Nancy strain infected SJL mice after treatment with different doses of Example 8.

Figure 6 is a bar chart showing the results from average pancreatitis scoring as well as average Ct values from PCR detection of virus titer, in Coxsackie B3, Nancy strain infected SJL mice after treatment with at a fixed dose of 50 mg/kg/day for Example 2, 8 and 20, respectively. Coxsackie B3, Nancy strain infected SJL mice receiving no treatment were used as controls.

DETAILED DESCRIPTION OF THE INVENTION

[0027] "Pharmaceutically acceptable" means being useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes being useful for veterinary use as well as human pharmaceutical use.


[0028] "Treatment" as used herein includes prophylaxis of the named disorder or condition, or amelioration or elimination (i.e. cure) of the disorder once it has been established.

[0029] An "effective amount" refers to an amount of a compound that confers a therapeutic effect on the treated subject. The therapeutic effect may be objective (i.e., measurable by some test or marker, e.g. no measurable virus titre in a biological sample from the treated subject) or subjective (i.e., subject gives an indication of or feels an effect).


[0030] Unless otherwise stated or indicated, the term "C1-C6 alkyl" denotes a straight or branched alkyl group having from 1 to 6 carbon atoms, e.g. methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl and straight- and branched-chain pentyl and hexyl.

[0031] Unless otherwise stated or indicated, the term "halogen" (or "halo") refers to fluorine (F), chlorine (Cl), or bromine (Br).


[0032] A moiety of the type RO is a moiety of formula




A moiety of the type RR'NC(O) is a moiety of formula




A moiety of the type RC(O)N(R') is a moiety of formula




A moiety of the type RS(O)₂ is a moiety of formula




A moiety of the type RS(O)₂N(R') is a moiety of formula




A moiety of the type RR'NS(O)₂ is a moiety of formula




A moiety of the type RR'N is a moiety of formula



A moiety of the type RC(O) is a moiety of formula




A moiety of the type ROC(O) is a moiety of formula




[0033] The term "heterocyclyl" (or "heterocyclic ring") refers to a saturated or unsaturated, aromatic or non-aromatic cyclic moiety containing not only carbon atoms, but also at least one other atom in the ring, e.g. selected from nitrogen (N), sulphur (S) and oxygen (O). When aromatic, the heterocyclyl also may be referred to as "heteroaryl", which refers to an aromatic ring containing at least one ring heteroatom, such as furyl, isoxazolyl, isothiazolyl, imidazolyl, pyridyl, pyrrolyl, pyrazolyl, pyrimidinyl, pyridazinyl, pyrazinyl, oxadiazolyl, oxazolyl, thienyl, thiadiazolyl, thiazolyl, triazolyl, and tetrazolyl.

[0034] The term "aromatic", as used herein, refers to an unsaturated cyclic moiety that has an aromatic character, while the term "non-aromatic", as used herein, refers to a cyclic moiety, that may be saturated or unsaturated, e.g. polyunsaturated, but that does not have an aromatic character.


[0035] The term "benzyl" refers to a moiety of formula $C_6H_5CH_2-$, i.e.;




The term "pyridyl" (or pyridinyl) refers to a moiety of formula




The term "3-pyridyl" (or "pyridin-3-yl") refers to a moiety of formula




A 3-pyridyl substituted with a moiety R_1 in 6-position (e.g. 6-methyl-3-pyridyl) is a compound of formula




The term "4-pyridyl" (or pyridin-4-yl) refers to a moiety of formula




The term "thienyl" refers to a moiety of formula




The term "2-thienyl" refers to a moiety of formula



The term "furyl" refers to a moiety of formula



The term "2-furyl" refers to a moiety of formula



[0036] A "non-enveloped single-stranded (+) RNA viral infection" refers to an infection with a


non-enveloped single-stranded (+) RNA virus. A "non-enveloped virus" is a virus lacking viral envelope. A "single-stranded (+) RNA virus" is a virus having genetic material which is single-stranded RNA and which RNA can be immediately translated to viral protein by the cell infected by the virus.

[0037] The term "mammal" refers to a human or any mammalian animal, e.g. a primate, a farm animal, a pet animal, or a laboratory animal. Examples of such animals are monkeys, cows, sheep, goats, horses, pigs, dogs, cats, rabbits, mice, rats etc. Preferably, the mammal is a human. In some embodiments, however, the mammal is an animal, e.g. a farm animal, such as a cow, sheep, goat, horse, or pigs. In some other embodiments, the animal is a pet, e.g. a dog, a cat or a rabbit.

[0038] The term "excipient" refers to a pharmaceutically acceptable chemical, such as known to those of ordinary skill in the art of pharmacy to aid the administration of a medicinal agent. It is a compound that is useful in preparing a pharmaceutical composition, generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipients that are acceptable for veterinary use as well as human pharmaceutical use. Exemplary excipients include binders, surfactants, diluents, disintegrants, antiadherents, and lubricants.


[0039] In a compound of formula (I) as defined herein, X is N or CH; and Y is N and Z is C, or Y is C and Z is N. In some embodiments, X is CH, Y is N, and Z is C; or X is CH, Y is C, and Z is N; or X is N, Y is N, and Z is C. In some embodiments, X is CH, Y is N, and Z is C; or X is CH, Y is C, and Z is N. In some embodiments, X is CH, Y is C, and Z is N; or X is N, Y is N, and Z is C. In some embodiments, X is CH, Y is N, and Z is C; or X is N, Y is N, and Z is C.

[0040] In some embodiments, X is CH, i.e. the compound of formula (I) is a compound of formula (Ia)




wherein m, R₁, ring A, Y and Z are as defined herein.

[0041] In some embodiments, X is N, i.e. the compound of formula (I) is a compound of formula (Ib)




wherein m , R_1 , ring A, Y and Z are as defined herein.

[0042] In some embodiments, Y is C and Z is N, i.e. the compound of formula (I) is a compound of formula (Ic)




wherein m , R_1 , ring A, and X are as defined herein.

[0043] In some embodiments, Y is N and Z is C, i.e. the compound of formula (I) is a compound of formula (ld)




wherein m , R_1 , ring A, and X are as defined herein.

[0044] In some embodiments of a compound of formula (Ia), Y is C and Z is N, i.e. the compound may be represented by formula (le)




wherein m , R_1 , and ring A are as defined herein.

[0045] In some other embodiments of a compound of formula (Ia), Y is N and Z is C, i.e. the compound may be represented by formula (lf)




wherein m , R_1 , and ring A are as defined herein.


[0046] In some embodiments of a compound of formula (Ib), Y is N and Z is C, i.e. the compound may be represented by formula (lg)



wherein m , R_1 , and ring A are as defined herein.

[0047] In some embodiments of a compound of formula (Ib), Y is C and Z is N, i.e. the compound may be represented by formula (lh)





wherein m, R₁, and ring A are as defined herein.

[0048] In some of embodiments of a compound of formula (I), X is N only when Y is N and Z is C.

[0049] In a compound of formula (I), ring A is phenyl or 5- or 6-membered heteroaryl having one or more heteroatoms selected from O, S, and N. In some embodiments, ring A is 5- or 6-membered heteroaryl. In some other embodiments, ring A is phenyl or 6-membered heteroaryl. In still other embodiments, ring A is phenyl. In still other embodiments, ring A is phenyl or 5-membered heteroaryl. In some embodiments, ring A is 5-membered heteroaryl. In some other embodiments, ring A is 6-membered heteroaryl.

[0050] When ring A is 5- or 6-membered heteroaryl, said heteroaryl contains one or more heteroatoms selected from N, O and S. For example, said heteroaryl may contain 1, 2, 3, or 4 heteroatoms. In some embodiments, said heteroaryl contains 1, 2 or 3 heteroatoms. In some other embodiments, said heteroaryl contains or 1 or 2 heteroatoms selected from N, O and S. In still other embodiments, said heteroaryl contains 1 heteroatom selected from N, O and S.


[0051] When ring A is heteroaryl, each heteroatom is independently selected from N, O and S. In some embodiments, each heteroatom is independently selected from N and O. In still other embodiments each heteroatom is independently selected from N and S. In some particular embodiments, at least one heteroatom is N, e.g. each heteroatom is N. In some embodiments, the heteroaryl contains one heteroatom, which is N. In some other embodiments, the heteroaryl contains one heteroatom, which is O. In some other embodiments, the heteroaryl contains one heteroatom, which is S.

[0052] In some embodiments, when ring A is 5-membered heteroaryl, said heteroaryl contains one heteroatom selected from O and S, and optionally one or more nitrogen atoms, e.g. 1-3 N, or 1 or 2 N, e.g. 1 N. In some embodiments, said heteroaryl is thienyl or furyl, e.g. 2-thienyl or 2-furyl. In some embodiments, when ring A is 5-membered heteroaryl, said heteroaryl more particularly is thienyl, e.g. 2-thienyl.


[0053] In some embodiments, when ring A is 6-membered heteroaryl, each heteroatom of said heteroaryl is N. For example, in some embodiments, when ring A is 6-membered heteroaryl, said heteroaryl is pyridyl, e.g. 3-pyridyl or 4-pyridyl.

[0054] In some embodiments, when ring A is 5- or 6-membered heteroaryl, said heteroaryl is selected from thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl.


[0055] The compound of formula (I) comprises a moiety of formula (II)



In some embodiments, when ring A is phenyl or 6-membered heteroaryl, the moiety of formula (II) more particularly is a moiety of formula (IIa)



wherein W_1 and W_2 are independently selected from N, CH and CR_1 . In such embodiments, the compound of formula (I) may be represented by formula (Ij)




wherein W_1 , W_2 , X, Y and Z are as defined herein.

[0056] In some embodiments, one of W_1 and W_2 is different from N. In some embodiments, at least one of W_1 and W_2 is N. In some embodiments, at least one of W_1 and W_2 is different from CH. In some embodiments, at least one of W_1 and W_2 is different from CR_1 . In some embodiments, W_1 and W_2 are different from each other, i.e. W_1 and W_2 are not both N, not both CH and not both CR_1 .

[0057] In some particular embodiments of a compound of formula (Ij), W_1 is N, CH or CR_1 , and W_2 is N or CR_1 . In some other particular embodiments, W_1 is CH or CR_1 , and W_2 is N or CR_1 . In some other particular embodiments, W_1 is N or CH, and W_2 is N, CH or CR_1 . In some of these embodiments, at least one of W_1 and W_2 is different from CH. In still other embodiments of a compound of formula (Ij), either W_1 or W_2 is N, and the other one is selected from CH and CR_1 . In some of these embodiments, W_1 is N, and W_2 is CR_1 ; or W_1 is CH and W_2 is N.

[0058] In some further embodiments, W_1 is CH, i.e. the compound of formula (Ij) may be represented by formula (Ik)




wherein W_2 , X, Y and Z are as defined herein.

[0059] In some embodiments of a compound of formula (Ik), W_2 is N or CR_1 , e.g. W_2 is N. In some other embodiments of a compound of formula (Ik), W_2 is CH or CR_1 , e.g. W_2 is CR_1 .

[0060] In some other particular embodiments of a compound of formula (Ij), W_2 is CR_1 , i.e. the


compound of formula (Ij) may be represented by formula (Im)



wherein R_1 , W_1 , X , Y and Z are as defined herein.

[0061] In some embodiments of a compound of formula (Im), W_1 is N or CH, e.g. W_1 is N.

[0062] In some further embodiments, the moiety of formula (II)



is selected from a moiety comprising 5-membered heteroaryl, e.g. unsubstituted (m is 0) 5-membered heteroaryl, and a ring of formula (IIa) as defined herein; e.g. from unsubstituted 2-thienyl and a ring of formula (IIa) wherein W_1 is CH and W_2 is CR_1 , or W_1 is CH and W_2 is N, or W_1 is N and W_2 is CR_1 . In some further embodiments, the moiety of formula (II) is selected from unsubstituted 2-thienyl and a ring of formula (IIa) wherein W_1 is CH and W_2 is N, or W_1 is N and W_2 is CR_1 .

[0063] In a compound of formula (I), m is an integer that denotes the number of substituents on ring A. The integer m is 0, 1 or 2, i.e. ring A may be unsubstituted (m is 0) or substituted by 1 or 2 moieties R_1 (m is 1 or 2). In some embodiments, m is 0 or 1. In some other embodiments, m is 0. In still other embodiments, m is 1 or 2, in particular 1.

[0064] In some embodiments, when ring A is phenyl, m is different from 0. Thus, in some embodiments, when ring A is phenyl, m is 1 or 2, and when ring A is 5- or 6-membered heteroaryl, m is 0, 1 or 2. In some other embodiments, when ring A is phenyl, m is 1, and when ring A is 5- or 6-membered heteroaryl, m is 0 or 1. In still further embodiments, when ring A is phenyl, m is 1, and when ring A is 5- or 6-membered heteroaryl, m is 0. In some further embodiments, when ring A is phenyl, m is 1, when ring A is 5-membered heteroaryl, m is 0, and when ring A is 6-membered heteroaryl, m is 0 or 1.

[0065] In some embodiments, ring A is phenyl and m is different from 0. In some embodiments, ring A is phenyl and m is 1 or 2, or ring A is 5- or 6-membered heteroaryl and m is 0, 1 or 2. In some other embodiments, ring A is phenyl and m is 1, or ring A is 5- or 6-membered heteroaryl, and m is 0 or 1. In still further embodiments, ring A is phenyl, and m is 1, or ring A is 5- or 6-membered heteroaryl, and m is 0. In some further embodiments, ring A is phenyl, and m is 1, or ring A is 5-membered heteroaryl, and m is 0, or ring A is 6-membered heteroaryl, and m is 0 or 1.

[0066] In some embodiments, ring A is phenyl, and m is 0, 1 or 2, in particular 1 or 2. In some embodiments, ring A is phenyl, and m is 1.

[0067] In some embodiments, ring A is 5- or 6-membered heteroaryl, and m is 0 or 1. In some embodiments, ring A is 5- or 6-membered heteroaryl, and m is 0. In some embodiments, ring A is 5-membered heteroaryl, and m is 0. In some embodiments, ring A is 6-membered heteroaryl, and m is 0 or 1. In some embodiments, ring A is 6-membered heteroaryl, and m is 1. In some embodiments, ring A is 6-membered heteroaryl, and m is 0.

[0068] In a compound of formula (I), each moiety R_1 is independently selected from halogen, C1-C6 alkyl, R_2O , $R_3S(O)_2$, $R_4S(O)_2N(R_5)$, $R_6R_7NC(O)$, $R_8C(O)N(R_9)$, $R_{10}C(O)$, $R_{11}R_{12}N$, and $R_{13}R_{14}NS(O)_2$; and when m is 2, two R_1 attached to adjacent atoms of ring A, together with the atoms to which they are attached may form a 5- or 6-membered heterocyclic or carbocyclic ring. In some embodiments, each R_1 is independently selected from halogen, C1-C6 alkyl, R_2O , $R_3S(O)_2$, $R_4S(O)_2N(R_5)$, $R_6R_7NC(O)$, $R_8C(O)N(R_9)$, $R_{10}C(O)$, $R_{11}R_{12}N$, and $R_{13}R_{14}NS(O)_2$.

[0069] In some embodiments, each R_1 is independently selected from halogen, C1-C6 alkyl, R_2O , $R_3S(O)_2$, $R_4S(O)_2N(R_5)$, $R_8C(O)N(R_9)$, $R_{10}C(O)$, $R_{11}R_{12}N$, and $R_{13}R_{14}NS(O)_2$.

[0070] In some embodiments, each R_1 is independently selected from halogen, C1-C6 alkyl, R_2O , $R_3S(O)_2$, $R_4S(O)_2N(R_5)$, $R_6R_7NC(O)$, $R_{10}C(O)$, $R_{11}R_{12}N$, and $R_{13}R_{14}NS(O)_2$.

[0071] In some embodiments, each R_1 is independently selected from halogen, C1-C6 alkyl, R_2O , $R_3S(O)_2$, $R_4S(O)_2N(R_5)$, $R_6R_7NC(O)$, $R_8C(O)N(R_9)$, $R_{11}R_{12}N$, and $R_{13}R_{14}NS(O)_2$.

[0072] In some embodiments, each R_1 is independently selected from halogen, C1-C6 alkyl, R_2O , $R_3S(O)_2$, $R_4S(O)_2N(R_5)$, $R_6R_7NC(O)$, $R_8C(O)N(R_9)$, $R_{10}C(O)$, and $R_{13}R_{14}NS(O)_2$.

[0073] In some embodiments, each R_1 is independently selected from halogen, C1-C6 alkyl, R_2O , $R_3S(O)_2$, $R_4S(O)_2N(R_5)$, and $R_{13}R_{14}NS(O)_2$. In some embodiments, each R_1 is independently selected from halogen, C1-C6 alkyl, and R_2O .

[0074] In some embodiments, each R_1 is independently selected from R_2O , $R_3S(O)_2$, $R_4S(O)_2N(R_5)$, and $R_{13}R_{14}NS(O)_2$. In some embodiments, each R_1 is independently selected from $R_3S(O)_2$, $R_4S(O)_2N(R_5)$, and $R_{13}R_{14}NS(O)_2$.

[0075] In some further embodiments, each R_1 is independently selected from C1-C6 alkyl, R_2O , $R_3S(O)_2$, $R_4S(O)_2N(R_5)$, $R_6R_7NC(O)$, $R_8C(O)N(R_9)$, $R_{10}C(O)$, $R_{11}R_{12}N$, and $R_{13}R_{14}NS(O)_2$; in particular from C1-C6 alkyl, R_2O , $R_3S(O)_2$, $R_4S(O)_2N(R_5)$, and $R_{13}R_{14}NS(O)_2$; or from C1-C6 alkyl, R_2O , and $R_3S(O)_2$.

[0076] In some further embodiments, each R_1 is independently selected from halogen, C1-C6 alkyl, R_2O , and $R_3S(O)_2$.

[0077] Each one of the moieties R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} , R_{11} , R_{12} , R_{13} , R_{15} and R_{16} , when present, is independently selected from H and C1-C6 alkyl, e.g. from H and C1-C4 alkyl, or from H and C1-C3 alkyl, or from H, methyl and ethyl, in particular from H and methyl.

[0078] In some embodiments, each one of the moieties R_2 , R_3 , R_4 , R_8 , R_{10} , R_{15} and R_{16} , when present, is independently selected from C1-C6 alkyl, e.g. from C1-C4 alkyl, or from C1-C3 alkyl, or from methyl and ethyl, e.g. methyl; and each one of the moieties R_5 , R_6 , R_7 , R_9 , R_{11} , R_{12} , and R_{13} , when present, is independently selected from H and C1-C6 alkyl, e.g. from H and C1-C4 alkyl, or from H and C1-C3 alkyl, or from H, methyl and ethyl, or from H and methyl, in particular H.

[0079] In some embodiments, each one of the moieties R_2 , R_3 , R_4 , R_8 , R_{10} , R_{15} and R_{16} , when present, is independently selected from C1-C3 alkyl; and each one of the moieties R_{15} , R_6 , R_7 , R_9 , R_{11} , R_{12} , and R_{13} , and when present, is independently selected from H and C1-C3 alkyl.

[0080] In some embodiments, each one of the moieties R_2 , R_3 , R_4 , R_8 , R_{10} , R_{15} and R_{16} , when present, is independently selected from methyl and ethyl; and each one of the moieties R_5 , R_6 , R_7 , R_9 , R_{11} , R_{12} , and R_{13} , when present, is independently selected from H, methyl and ethyl.

[0081] In some particular embodiments, each one of the moieties R_2 , R_3 , R_4 , R_8 , R_{10} , R_{15} and R_{16} , when present, is methyl; and each one of the moieties R_5 , R_6 , R_7 , R_9 , R_{11} , R_{12} , and R_{13} , and when present, is H.

[0082] The moiety R_{14} is selected from H, C1-C6 alkyl, $R_{15}C(O)$, and $R_{16}OC(O)$. In some embodiments, R_{14} is H or C1-C6 alkyl, e.g. H or C1-C4 alkyl; or H or C1-C3 alkyl; or H, methyl or ethyl; in particular H or methyl; e.g. R_{14} is H. In some other embodiments, R_{14} is selected from H, $R_{15}C(O)$, and $R_{16}OC(O)$, e.g. from H and $R_{15}C(O)$, e.g. R_{14} is $R_{15}C(O)$. In still further embodiments, R_{14} is selected from C1-C6 alkyl, $R_{15}C(O)$, and $R_{16}OC(O)$; e.g. from $R_{15}C(O)$ and $R_{16}OC(O)$, e.g. R_{14} is $R_{16}OC(O)$. In some further embodiments, R_{14} is C1-C6 alkyl, e.g. C1-C4 alkyl; or C1-C3 alkyl; e.g. methyl or ethyl; in particular methyl.

[0083] When R_1 is C1-C6 alkyl, said alkyl more particularly may be C1-C4 alkyl, or C1-C3 alkyl, or C1-C2 alkyl, e.g. methyl.

[0084] When R_1 is halogen, said halogen e.g. may be F, Cl or Br; or F or Cl; in particular Cl. In some embodiments, R_1 is Cl or Br.

[0085] In some particular embodiments, each R_1 is independently selected from F, Cl, CH_3 , CF_3 , CH_3O , $CH_3S(O)_2$, $CH_3S(O)_2NH$, and $NH_2S(O)_2$; or from Cl, CH_3 , CH_3O , $CH_3S(O)_2$, $CH_3S(O)_2NH$, and $NH_2S(O)_2$; e.g. from CH_3 , CH_3O , $CH_3S(O)_2$, $CH_3S(O)_2NH$, and $NH_2S(O)_2$; or

from CH₃, CH₃O, and CH₃S(O)₂.

[0086] In a compound of formula (I), any alkyl may optionally be substituted by one or more halogen atoms. In some embodiments, when any alkyl is substituted by one or more halogen, the halogen is fluoro (F). In some embodiments, no halogen substitution is present on any alkyl.

[0087] It should be noted that any reference to a compound of formula (I) implicitly also is a reference to a compound of any of the embodiments of such a compound, as illustrated in the formulas (Ia) to (Im), unless otherwise indicated or apparent from the context. Furthermore, unless mutually exclusive, and whether illustrated herein or not, any combinations of the embodiments as illustrated by formulas (Ia) to (Im) is contemplated within the scope of formula (I). For example, in some embodiments, a compound of formula (Ia) also is a compound of formula (Ic), i.e. a compound as illustrated by formula (Ie). In some other embodiments, a compound of formula (Ia) also is a compound of formula (Id), i.e. a compound as illustrated by formula (If).

[0088] Likewise, in some embodiments, a compound of formula (Ia) also is a compound of formula (Ij). In some embodiments, a compound of formula (Ib) also is a compound of formula (Ij). In some embodiments, a compound of formula (Ic) also is a compound of formula (Ij). In some embodiments, a compound of formula (Id) also is a compound of formula (Ij).

[0089] In some embodiments of a compound of formula (I), X is CH, Y is N and Z is C, or X is CH, Y is C and Z is N; or X is N, and Y is N and Z is C; and ring A is phenyl, thienyl, or pyridyl, e.g. ring A is phenyl, 2-thienyl, 3-pyridyl, or 4-pyridyl. In some of these embodiments, when ring A is phenyl, m is 1, and when ring A is thienyl or pyridyl, m is 0 or 1; e.g., when ring A is phenyl, m is 1; when ring A is thienyl, m is 0; and when ring A is pyridyl, m is 0 or 1. In some of these embodiments, R₁ is halogen, C1-C6 alkyl, R₂O, R₃S(O)₂, R₄S(O)₂N(R₅), or R₁₃R₁₄NS(O)₂; each one of R₂, R₃, R₄, R₅, R₁₃ and R₁₄ is independently selected from H and C1-C6 alkyl; e.g. from H and C1-C3 alkyl, and any alkyl is optionally substituted by one or more halogen.

[0090] In some particular embodiments of a compound of formula (I),
 X is CH, Y is N, and Z is C; or X is CH, Y is C, and Z is N; or X is N, Y is N, and Z is C;
 ring A is phenyl or 5- or 6-membered heteroaryl having one heteroatom, which heteroatom is selected from N, O and S;
 m is 0 or 1;
 each R₁ is independently selected from halogen, C1-C6 alkyl, R₂O, R₃S(O)₂, R₄S(O)₂N(R₅), R₆R₇NC(O), R₈C(O)N(R₉), R₁₀C(O), R₁₁R₁₂N, and R₁₃R₁₄NS(O)₂;
 each one of R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, and R₁₃ is independently selected from H and C1-C6 alkyl;
 R₁₄ is selected from H, C1-C6 alkyl, R₁₅C(O), and R₁₆OC(O),
 R₁₅ and R₁₆ are independently selected from H and C1-C6 alkyl; and
 any alkyl is optionally substituted by one or more halogen.

[0091] In some other particular embodiments of a compound of formula (I),
 X is CH, Y is N, and Z is C; or X is CH, Y is C, and Z is N; or X is N, Y is N, and Z is C;
 ring A is phenyl or 5- or 6-membered heteroaryl having one heteroatom, which heteroatom is selected from N, O and S;
 m is 0 or 1;
 each R_1 is independently selected from halogen, C1-C6 alkyl, R_2O , $R_3S(O)_2$, $R_4S(O)_2N(R_5)$, and $R_{13}R_{14}NS(O)_2$;
 each one of R_2 , R_3 , R_4 , R_5 , R_{13} and R_{14} is independently selected from H and C1-C6 alkyl;
 and any alkyl is optionally substituted by one or more halogen.

[0092] In some other particular embodiments of a compound of formula (I),
 X is CH, Y is N, and Z is C; or X is CH, Y is C, and Z is N; or X is N, Y is N, and Z is C; ring A is phenyl, 2-thienyl, 3-pyridyl, or 4-pyridyl;
 m is 0 or 1;
 each R_1 is independently selected from halogen, C1-C6 alkyl, R_2O , $R_3S(O)_2$, $R_4S(O)_2N(R_5)$, and $R_{13}R_{14}NS(O)_2$;
 each one of R_2 , R_3 , R_4 , R_5 , R_{13} and R_{14} is independently selected from H and C1-C6 alkyl;
 and any alkyl is optionally substituted by one or more halogen.

[0093] In some other particular embodiments of a compound of formula (I),
 X is CH, Y is N, and Z is C; or X is CH, Y is C, and Z is N; or X is N, Y is N, and Z is C; ring A is phenyl, 2-thienyl, 3-pyridyl, or 4-pyridyl;
 m is 0 or 1;
 each R_1 is independently selected from halogen, C1-C3 alkyl, R_2O , $R_3S(O)_2$, $R_4S(O)_2N(R_5)$, and $R_{13}R_{14}NS(O)_2$;
 each one of R_2 , R_3 , R_4 , R_5 , R_{13} and R_{14} is independently selected from H and C1-C3 alkyl;
 and any alkyl is optionally substituted by one or more halogen.

[0094] In some of the above mentioned particular embodiments, X is CH, Y is N, and Z is C. In some other of the above mentioned particular embodiments, X is CH, Y is C, and Z is N. In still other of the above mentioned particular embodiments, X is N, Y is N, and Z is C.

[0095] In some of the above mentioned particular embodiments, when ring A is phenyl, m is different from 0.

[0096] In some other of the above mentioned particular embodiments, when any alkyl is optionally substituted by one or more halogen, said halogen is F.

[0097] In some other of the above mentioned particular embodiments, ring A is 5- or 6-membered heteroaryl. In some of these embodiments, ring A is thienyl, e.g. 2-thienyl. In some other of these embodiments, ring A is a ring of formula (IIa) as defined herein, wherein at least one of W_1 and W_2 is N.

[0098] In some other of the above mentioned particular embodiments, ring A is phenyl or 6-membered heteroaryl.

[0099] In some embodiments, the compound is a compound of formula (Id), more particularly a compound of formula (Ig), ring A is 5- or 6-membered heteroaryl, and m is 0 or 1.

[0100] In some of these embodiments, the compound is a compound of formula (Ig), ring A is 5- or 6-membered heteroaryl, and m is 0. In some of these embodiments, the compound is a compound of formula (Ig), ring A is 5-membered heteroaryl, and m is 0.

[0101] In some other of these embodiments, the compound is a compound of formula (Ig), ring A is 6-membered heteroaryl, and m is 0 or 1. In some of these embodiments, the compound is a compound of formula (Ig), ring A is 6-membered heteroaryl, and m is 0.


[0102] In some embodiments, the compound is a compound of formula (Ib), ring A is 5- or 6-membered heteroaryl, and m is 0 or 1. In some of these embodiments, the compound is a compound of formula (Ib), ring A is 5- or 6-membered heteroaryl, and m is 0. In some of these embodiments, the compound is a compound of formula (Ib), ring A is 5-membered heteroaryl, and m is 0. For example, in some embodiments, the compound is a compound of formula (Ib), ring A is 4-pyridyl or 2-thienyl and m is 0. In some embodiments, the compound is a compound of formula (Id), ring A is 4-pyridyl or 2-thienyl and m is 0. In some of these embodiments, the compound is a compound of formula (Ig), ring A is 4-pyridyl or 2-thienyl, and m is 0.

[0103] In some other embodiments, the compound is a compound of formula (Ib), (Id) or (Ig), ring A is pyridyl or thienyl, and m is 0 or 1. In some of these embodiments, the compound is a compound of formula (Ig).


[0104] In some of the above embodiments, m is 0 when ring A is thienyl.

[0105] In some embodiments of a compound of formula (I), ring A is 4-pyridyl, or 2-thienyl, and m is 0; or ring A is phenyl, 3-pyridyl, or 4-pyridyl, and m is 1.

[0106] In some embodiments, the moiety of formula (II)



is a moiety selected from



wherein R₁ is as defined herein, e.g. R₁ is selected from halogen, C1-C6 alkyl, R₂O, R₃S(O)₂, R₄S(O)₂N(R₅), and R₁₃R₁₄NS(O)₂.

[0107] In some embodiments, the moiety of formula (II) is selected from phenyl, 4-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-methylsulfonylphenyl, 4-sulfamoylphenyl, 4-

(methylsulfonamido)phenyl, pyridin-4-yl, 6-methylpyridin-3-yl, 6-trifluoromethylpyridin-3-yl, 6-methoxypyridin-3-yl, and 2-thienyl. In some further embodiments, the moiety of formula (II) is selected from 4-methoxyphenyl, 4-chlorophenyl, 4-methylsulfonylphenyl, 4-sulfamoylphenyl, 4-(methylsulfonamido)phenyl, pyridin-4-yl, 6-methylpyridin-3-yl, 6-methoxypyridin-3-yl, and 2-thienyl.

[0108] In some further embodiments,

X is CH or N;

Y is N and Z is C; or Y is C and Z is N;

ring A is phenyl, 3-pyridyl, 4-pyridyl, or 2-thienyl,

m is 0 or 1;

each R_1 is independently selected from C1-C6 alkyl, R_2O , and $R_3S(O)_2$;

each one of R_2 and R_3 is independently selected from C1-C6 alkyl; and

any alkyl is optionally substituted by one or more halogen, e.g. one or more F.

[0109] In still further embodiments,

X is CH or N;

Y is N and Z is C; or Y is C and Z is N;

ring A is phenyl, 3-pyridyl, 4-pyridyl, or 2-thienyl,

m is 0 or 1;

each R_1 is independently selected from C1-C3 alkyl, R_2O , and $R_3S(O)_2$;

each one of R_2 and R_3 is independently selected from C1-C3 alkyl; and

any alkyl is optionally substituted by one or more halogen, e.g. one or more F.

[0110] In still further embodiments,

X is CH or N;

Y is N and Z is C; or Y is C and Z is N;

ring A is 3-pyridyl, 4-pyridyl, or 2-thienyl,

m is 0 or 1; e.g. m is 0 when ring A is 4-pyridyl or 2-thienyl and m is 1 when ring A is 3-pyridyl;

each R_1 is independently selected from C1-C3 alkyl, R_2O , and $R_3S(O)_2$;

each one of R_2 and R_3 is independently selected from C1-C3 alkyl; and

any alkyl is optionally substituted by one or more halogen, e.g. one or more F.

[0111] In some further embodiments, e.g. in some embodiments of formula (Ij),

X is CH or N;

Y is N and Z is C; or Y is C and Z is N;

ring A is phenyl, 3-pyridyl, or 4-pyridyl;

m is 0 or 1; e.g. m is 0 when ring A is 4-pyridyl, and m is 1 when ring A is phenyl or 3-pyridyl;

each R_1 is independently selected from C1-C6 alkyl, R_2O , and $R_3S(O)_2$;

each one of R_2 and R_3 is independently selected from C1-C6 alkyl; and

any alkyl is optionally substituted by one or more halogen, e.g. one or more F.

[0112] In still further embodiments, e.g. in some embodiments of formula (Ij),

X is CH or N;

Y is N and Z is C; or Y is C and Z is N;

ring A is 3-pyridyl or 4-pyridyl;

m is 0 or 1; e.g. m is 0 when ring A is 4-pyridyl, and m is 1 when ring A is 3-pyridyl;

each R_1 is independently selected from C1-C3 alkyl, R_2O , and $R_3S(O)_2$;

each one of R_2 and R_3 is independently selected from C1-C6 alkyl; and

any alkyl is optionally substituted by one or more halogen, e.g. one or more F.

[0113] In still further embodiments,

X is CH or N;

Y is N and Z is C; or Y is C and Z is N;

ring A is phenyl, 3-pyridyl, 4-pyridyl, or 2-thienyl;

m is 0 or 1;

each R_1 is independently selected from methyl, CH_3O , and $CH_3S(O)_2$; and any methyl is optionally substituted by one or more F.

[0114] In still further embodiments,

X is CH or N;

Y is N and Z is C; or Y is C and Z is N;

ring A is phenyl, 3-pyridyl, 4-pyridyl, or 2-thienyl;

m is 0 or 1;

each R_1 is independently selected from methyl, CH_3O , and $CH_3S(O)_2$; and any methyl is optionally substituted by one or more F.

[0115] In still further embodiments,

X is CH or N;

Y is N and Z is C; or Y is C and Z is N;

ring A is 3-pyridyl, 4-pyridyl or 2-thienyl;

m is 0 or 1;

each R_1 is independently selected from methyl, CH_3O , and $CH_3S(O)_2$; and any methyl is optionally substituted by one or more F.

[0116] In still further embodiments,

X is CH or N;

Y is N and Z is C; or Y is C and Z is N;

ring A is 3-pyridyl or 4-pyridyl;

m is 0 or 1;

each R_1 is independently selected from methyl, CH_3O , and $CH_3S(O)_2$; and any methyl is optionally substituted by one or more F.

[0117] In some of these embodiments, when ring A is 3-pyridyl, 4-pyridyl or phenyl, the moiety (II) is a moiety of formula (IIa).

[0118] In some embodiments, when ring A is 3-pyridyl, m is 1 or 2 and one R_1 is attached in 6-

position on the pyridyl ring.

[0119] In still further embodiments, the moiety of formula (II) is 5-membered unsubstituted heteroaryl, e.g. thienyl or furyl, in particular thienyl. In still further embodiments, the moiety of formula (II) is 2-thienyl or 2-furyl, in particular 2-thienyl. In some of these embodiments, the compound of formula (I) is a compound of formula (Id).

[0120] The compounds of formula (I) also may be transformed into suitable, pharmaceutically acceptable salts. The term pharmaceutically acceptable salt of a compound refers to a salt that is pharmaceutically acceptable, as defined herein, and that possesses the desired pharmacological activity of the parent compound. Pharmaceutically acceptable salts include acid addition salts formed with inorganic acids, e.g. hydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid, phosphoric acid; or formed with organic acids, e.g. acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, hydroxynaphtoic acid, 2-hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, muconic acid, 2-naphthalenesulfonic acid, propionic acid, salicylic acid, succinic acid, tartaric acid, p-toluenesulfonic acid, trimethylacetic acid, etc.

[0121] In the preparation of acid addition salts, preferably such acid are used which form suitably therapeutically acceptable salts. Examples of such acids are hydrohalogen acids, sulfuric acid, phosphoric acid, nitric acid, aliphatic, alicyclic, aromatic or heterocyclic carboxylic or sulfonic acids, such as formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid, pyruvic acid, p-hydroxybenzoic acid, embonic acid, methanesulfonic acid, ethanesulfonic acid, hydroxyethanesulfonic acid, halogenbenzenesulfonic acid, toluenesulfonic acid or naphthalenesulfonic acid.

[0122] Whenever a chiral atom is present in a chemical structure, it is intended that all stereoisomers associated with that chiral atom are encompassed by the structure, unless otherwise specified. Using the Cahn-Ingold-Prelog RS notational system, any asymmetric atom may be present in the (R)- or (S)-configuration, and the compound may be present as a mixture of its stereoisomers, e.g. a racemic mixture, or one stereoisomer only, each being within the scope of the present invention.

[0123] The present invention includes pharmaceutical compositions comprising at least one compound of formula (I), or an individual isomer, racemic or non-racemic mixture of isomers or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable excipient, e.g. a carrier, and optionally other therapeutic and/or prophylactic ingredients.

[0124] A pharmaceutical composition according to the invention may be for topical (local) or systemic administration, e.g. for enteral administration, such as rectal or oral administration, or for parenteral administration to a mammal (especially a human), and comprises a

therapeutically effective amount of a compound according to the invention or a pharmaceutically acceptable salt thereof, as active ingredient, in association with a pharmaceutically acceptable excipient, e.g. a pharmaceutically acceptable carrier. The therapeutically effective amount of the active ingredient is as defined herein and depends e.g. on the species of mammal, the body weight, the age, the individual condition, individual pharmacokinetic data, the disease to be treated and the mode of administration.

[0125] For enteral, e.g. oral, administration, the compounds of the invention may be formulated in a wide variety of dosage forms. The pharmaceutical compositions and dosage forms may comprise a compound or compounds of the present invention or pharmaceutically acceptable salt(s) thereof as the active component. The pharmaceutically acceptable carriers may be either solid or liquid. Solid form preparations include powders, tablets, pills, lozenges, capsules, cachets, suppositories, and dispersible granules. A solid carrier may be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component. In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatine, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The formulation of the active compound may comprise an encapsulating material as carrier, providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is in association with it.

[0126] Other forms suitable for oral administration include liquid form preparations including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions, or solid form preparations which are intended to be converted shortly before use to liquid form preparations. Emulsions may be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents, for example, such as lecithin, sorbitan monooleate, or acacia. Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents. Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents. Solid form preparations include solutions, suspensions, and emulsions, and may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilising agents, and the like.

[0127] Exemplary compositions for rectal administration include suppositories which can contain, for example, a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.

[0128] The compounds of the invention also may be administered parenterally, e.g. by

inhalation, injection or infusion, e.g. by intravenous, intraarterial, intraosseous, intramuscular, intracerebral, intracerebroventricular, intrasynovial, intrasternal, intrathecal, intralesional, intracranial, intracutaneous and subcutaneous injection or infusion. Thus, for parenteral administration, the pharmaceutical compositions of the invention may be in the form of a sterile injectable or infusible preparation, for example, as a sterile aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (e.g., Tween 80), and suspending agents. The sterile injectable or infusible preparation may also be a sterile injectable or infusible solution or suspension in a non-toxic parenterally acceptable diluent or solvent. For example, the pharmaceutical composition may be a solution in 1,3-butanediol. Other examples of acceptable vehicles and solvents that may be employed in the compositions of the present invention include, but are not limited to, mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant.

[0129] Solutions for parenteral use also may contain suitable stabilizing agents, and if necessary, buffer substances. Suitable stabilizing agents include antioxidizing agents, such as sodium bisulfate, sodium sulfite or ascorbic acid, either alone or combined, citric acid and its salts and sodium EDTA. Parenteral solutions may also contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.

[0130] For inhalation or nasal administration, suitable pharmaceutical formulations are as particles, aerosols, powders, mists or droplets, e.g. with an average size of about 10 μm in diameter or less. For example, compositions for inhalation may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilising or dispersing agents known in the art.

[0131] The pharmaceutical compositions of the invention also may be administered topically, to the skin or to a mucous membrane. For topical application, the pharmaceutical composition may be e.g. a lotion, a gel, a paste, a tincture, a transdermal patch, or a gel for transmucosal delivery.

[0132] The composition may be formulated as a suitable ointment containing the active components suspended or dissolved in a carrier. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.

[0133] Alternatively, the pharmaceutical composition may be formulated as a suitable lotion or

cream containing the active compound suspended or dissolved in a carrier. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

[0134] The pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation.

[0135] Suitable pharmaceutical excipients, e.g. carriers, and methods of preparing pharmaceutical dosage forms are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in art of drug formulation. The pharmaceutical compositions may comprise from approximately 1 % to approximately 95%, preferably from approximately 20% to approximately 90% of a compound of the invention, together with at least one pharmaceutically acceptable excipient.

[0136] In general, the compounds of the invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. Suitable daily dosages typically ranges from 1 to 1000 mg, e.g. 1-500 mg, or 1-50 mg of the compound of formula (I), or an equivalent amount of a pharmaceutically acceptable salt thereof, depending upon numerous factors such as the severity of the disease to be treated, the age and relative health of the patient, the potency of the compound used, the route and form of administration, and the indication towards which the administration is directed, etc. One of ordinary skill in the art of treating such diseases will be able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this application, to ascertain a therapeutically effective amount of the compounds of the present invention for a given disease. Compounds of the invention may be administered as pharmaceutical formulations including those suitable for enteral or parenteral administration. The preferred manner of administration is generally oral using a convenient daily dosage regimen which can be adjusted according to the degree of affliction.

[0137] The compounds of the present invention are contemplated as useful for the treatment of diseases caused by RNA viral infection in a mammal, e.g. non-enveloped single-stranded (+) RNA viral infection, in particular diseases caused by picornaviruses, i.e. viruses belonging to the family *Picornaviridae*. In some embodiments the picornavirus is selected from an enterovirus, a rhinovirus, a hepatovirus, a cardiovirus, an aphthovirus, a poliovirus, a parechovirus, an erbovirus, a kobuvirus, a teschovirus, a coxsackie virus; e.g. from an enterovirus, a rhinovirus, a hepatovirus, a poliovirus, a coxsackie virus. In some embodiments, when the compound of formula (I) is intended for veterinary use, the virus may be selected from an aphthovirus, and a teschovirus.

[0138] Diseases that are considered to be linked to, caused by, or otherwise associated with a viral infection, e.g. by a picornavirus, are e.g. pancreatitis, poliomyelitis, encephalitis, meningitis, sepsis, cancer, such as breast, prostate, ovarian and colorectal cancer, paralysis, myocarditis, diabetes, common cold, hand-foot-and-mouth disease, herpangina, pleurodynia, diarrhea, mucocutaneous lesions, respiratory illness, conjunctivitis, myositis, and chronic fatigue syndrome, as well as neurodegenerative diseases such as multiple sclerosis, Parkinson's

disease, amyotrophic lateral sclerosis, Alzheimer's disease, and Huntington's disease.

[0139] The compounds of the present invention further are contemplated as useful for the treatment of diseases caused by impaired and/or abnormal autophagy. Diseases that are considered to be linked to impaired or abnormal autophagy, are, for example, cancer, cardiac diseases, diabetes, inflammatory diseases, neuropsychiatric diseases, and neurodegenerative diseases such as multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, and Huntington's disease.

[0140] The compound of the present invention is a PI4 kinase inhibitor and as such it is considered as capable of having a usefulness in the treatment of various conditions where inhibition of a PI4 kinase is considered beneficial, e.g. a condition selected from e.g. pancreatitis, poliomyelitis, encephalitis, meningitis, sepsis, cancer, such as breast, prostate, ovarian and colorectal cancer, paralysis, cardiac diseases, such as myocarditis, diabetes, common cold, hand-foot-and-mouth disease, herpangina, pleurodynia, diarrhea, mucocutaneous lesions, respiratory illness, conjunctivitis, myositis, chronic fatigue syndrome, neuropsychiatric diseases, neurodegenerative diseases such as multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, and Huntington's disease, and inflammatory conditions.

[0141] The present invention consequently includes a compound of formula (I) for use in the treatment of any of the above mentioned diseases; a pharmaceutical composition for use in the treatment of any of the above mentioned diseases; the use of a compound of formula (I) in the manufacturing of a medicament for the treatment of any of the above mentioned diseases; and a method of treatment of any of the above mentioned diseases, by administering a compound of formula (I) to an animal or human in need of such treatment. Preferably, the compound of formula (I) is used for the treatment of a human patient. In some embodiments, however, the compound of formula (I) is used for the treatment of an animal (i.e. non-human patient), such as an animal as mentioned herein.









[0142] Compounds of the invention may be prepared by the person of ordinary skill in the art using his knowledge within the field of chemical synthesis, in light of the illustrating non-limiting examples that will follow herein below and by referring to the literature within the field.








EXAMPLES







[0143] Compounds of the invention were synthesized by following the General Procedures 1-3, described herein below. Their structural formulas and chemical names are given in **Table 1**.

Table 1

Ex.	Structural formula	Chemical name
1		3-(1,3-dimethyl-1H-indazol-5-yl)-2,6-dimethyl-N-(pyridin-4-ylmethyl)imidazo[1,2-b]pyridazin-8-amine
2		3-(1,3-dimethyl-1H-indazol-5-yl)-2,6-dimethyl-N-((6-methylpyridin-3-yl)methyl)imidazo[1,2-b]pyridazin-8-amine
3		N-(4-chlorobenzyl)-3-(1,3-dimethyl-1H-indazol-5-yl)-2,6-dimethylimidazo[1,2-b]pyridazin-8-amine
4		3-(1,3-dimethyl-1H-indazol-5-yl)-N-((6-methoxypyridin-3-yl)methyl)-2,6-dimethylimidazo[1,2-b]pyridazin-8-amine
5		3-(1,3-dimethyl-1H-indazol-5-yl)-2,6-dimethyl-N-(thiophen-2-ylmethyl)imidazo[1,2-b]pyridazin-8-amine
6		3-(1,3-dimethyl-1H-indazol-5-yl)-N-(4-methoxybenzyl)-2,6-dimethylimidazo[1,2-b]pyridazin-8-amine
7		3-(1,3-dimethyl-1H-indazol-5-yl)-2,6-dimethyl-N-(4-(methylsulfonyl)benzyl)imidazo[1,2-b]pyridazin-8-amine
8		3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine

Ex.	Structural formula	Chemical name
		
9		3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-((6-methylpyridin-3-yl)methyl)pyrazolo [1,5-a]pyrimidin-7-amine
10		3-(1,3-dimethyl-1H-indazol-5-yl)-N-(4-methoxybenzyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amine
11		N-(4-chlorobenzyl)-3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amine
12		3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-(4-(methylsulfonyl)benzyl)pyrazolo[1,5-a]pyrimidin-7-amine
13		4-(((3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)amino)methyl)benzenesulfonamide
14		3-(1,3-dimethyl-1H-indazol-5-yl)-N-((6-methoxypyridin-3-yl)methyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amine
15		3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-(thiophen-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
16		N-(4-(((3-(1,3-dimethyl-1H-indazol-5-

Ex.	Structural formula	Chemical name
		yl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)amino)methyl)phenyl)methanesulfonamide
17		3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-((6-trifluoromethylpyridin-3-yl)methyl)pyrazolo[1,5-a]pyrimidin-7-amine
18		N-(benzyl)-3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amine
19		N-(4-fluorobenzyl)-3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amine
20		8-(1,3-dimethyl-1H-indazol-5-yl)-2,7-dimethyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
21		8-(1,3-dimethyl-1H-indazol-5-yl)-N-(4-methoxybenzyl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine
22		8-(1,3-dimethyl-1H-indazol-5-yl)-2,7-dimethyl-N-((6-methylpyridin-3-yl)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
23		4-(((8-(1,3-dimethyl-1H-indazol-5-yl)-2,7-


Ex.	Structural formula	Chemical name
		dimethylpyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)benzenesulfonamide
24		N-(4-chlorobenzyl)-8-(1,3-dimethyl-1H-indazol-5-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine
25		8-(1,3-dimethyl-1H-indazol-5-yl)-2,7-dimethyl-N-(4-(methylsulfonyl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
26		N-(4-(((8-(1,3-dimethyl-1H-indazol-5-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)methanesulfonamide
27		8-(1,3-dimethyl-1H-indazol-5-yl)-2,7-dimethyl-N-(thiophen-2-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
28		8-(1,3-dimethyl-1H-indazol-5-yl)-N-((6-methoxypyridin-3-yl)methyl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine

General Procedures:

[0144] Reactions were performed in flame-dried sealed tubes or oven-dried glassware under a positive pressure of argon or nitrogen, unless otherwise noted. Air- and moisture-sensitive liquids and solutions were transferred via syringe. Diethyl ether (Et₂O) and tetrahydrofuran (THF) were distilled from sodium/benzophenone-ketyl. Dichloromethane (CH₂Cl₂) was distilled


from calcium hydride. All other chemicals were obtained from commercial vendors and were used without further purification unless noted otherwise. Molecular sieves were activated at 350 °C and were crushed immediately prior to use, then flame-dried under vacuum. Reactions were monitored by thin layer chromatography (TLC) with 0.25-mm E. Merck pre-coated silica gel plates. Organic solutions were concentrated by rotary evaporation below 50 °C. Flash column chromatography was performed employing 60-120 and 230-400 mesh silica gel. Yields refer to chromatographically and spectroscopically pure compounds unless otherwise noted. ^1H and ^{13}C spectra were recorded on a Bruker AVANCE III HD 400 MHz spectrometer. Chemical shifts are expressed in parts per million (δ scale) downfield from tetramethylsilane and are referenced to the residual resonance in the NMR solvent (CHCl_3 : δ 7.26 for ^1H NMR, δ 77.16 for ^{13}C NMR). LC-MS was performed on an Agilent XCT Ion Trap equipped with chemstation and Bruker daltonics software.

[0145] In the context of the General Procedures 1-3, described herein below, the term $\text{R}_\text{A}\text{NH}_2$ refers to an amine of the general formula (III)



wherein m , R_1 , and ring A are as described herein.

[0146] Tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole, used in the General Procedures 1-3, was synthesized by the below 2-step procedure illustrated in the following reaction scheme:



Step 1


[0147] To a stirred solution of 1-(5-bromo-2-fluoro-phenyl)-ethanone (10.0 g, 0.046 mol) in pyridine (50 mL) was added methyl hydrazine (2.7 mL, 0.050 mol) at room temperature. The resulting reaction mass was stirred at 100 °C for 16 hours. The crude product obtained after complete evaporation of the volatiles was diluted with water (50 mL) and extracted with ethyl acetate (100 mL*2). The organic layers were combined, dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain the product as a pale yellow solid. The crude product was purified by silica gel (230-400) column chromatography (15% ethyl acetate in hexane) to obtain 5-bromo-1,3-dimethyl-1H-indazole as a pale yellow oil (5.4 g, 52.4%).

Step 2

[0148] To a stirred solution of 5-bromo-1,3-dimethyl-1H-indazole (5.4 g, 0.023 mol) and 4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[[1,3,2]dioxaborolanyl] (7.3 g, 0.0287 mol) in dioxane (54 mL, 10 V) were added potassium acetate (7.05 g, 0.0719 mol) and palladium tetrakis (1.38 g, 0.0011 mol) under room temperature. The resulting reaction mass was stirred at 100 °C over a period of 3 hours. The reaction was monitored by TLC. The reaction mass was diluted with ethyl acetate (200 mL) and filtered through a celite pad. The organic layer was washed with water (500 mL), brine (250 mL), dried over anhydrous sodium sulphate and concentrated. The crude product obtained was purified by silica gel (230-400) column chromatography (15% ethyl acetate in hexane) to obtain tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole as an off-white solid (5.2 g, 80%).

General Procedure 1: Synthesis of imidazopyridazine derivatives (Scheme 1)

[0149]



Scheme 1

Step 1

[0150] To a solution of 6-methyl-pyridazin-3-ylamine, A (2.0 g, 0.018 mol) in acetonitrile (60 mL, 30 V) was added N-bromo succinamide (3.92 g, 0.022 mol) under room temperature. The reaction mass was stirred at room temperature for 2 hours. The reaction was monitored by TLC. The crude reaction mass obtained upon evaporation of the volatiles was purified by silica gel (60-120) column chromatography (3% methanol in dichloromethane) to obtain 4-bromo-6-methyl-pyridazin-3-ylamine, B, (0.6 g, 30%) as a dark brown solid.

Step 2

[0151] To a solution of B (0.6 g, 3.1 mmol) in ethanol (6 mL, 10 V) was added chloro acetone

(0.4 mL, 4.4 mmol) under room temperature. The resulting reaction mass was stirred at reflux temperature for 16 hours. The reaction was monitored by TLC. The crude reaction mass obtained upon evaporation of the volatiles was basified with saturated sodium bicarbonate and extracted with dichloromethane (100 mL). The organic layer was separated, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The crude product obtained was purified by silica gel (230-400) column chromatography (1.5% methanol in dichloromethane) to obtain 8-bromo-2,6-dimethyl-imidazo[1,2-b]pyridazine, C, (0.15 g, 20%) as a pale yellow solid.

Step 3

[0152] To a solution of C (0.33 g, 1.4 mmol) and amine $R_A\text{NH}_2$ (0.0027 mol, 1.3 eq) in toluene (10 mL, 30 V) under argon atmosphere in a sealed tube were added cesium carbonate (1.0 g, 2.9 mmol) and BINAP (46 mg, 0.07 mmol) at room temperature. The resulting reaction mass was degassed for 5 minutes, palladium acetate (17 mg, 0.07 mmol) was added and stirring was continued at 100 °C for a period of 16 hours. The resulting reaction mass was diluted with ethyl acetate (100 mL) and filtered through celite pad. The ethyl acetate layer was washed with water (50 mL) and brine (50 mL). The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The crude product obtained was purified by silica gel (230-400) column chromatography (3% methanol in dichloromethane) to obtain compound D.

Step 4

[0153] To a stirred solution of compound D (1.0 eq) in acetonitrile (10 mL, 10 V) was added N-iodo succinamide (0.9 eq) under ice temperature. The resulting reaction mass was stirred at ice temperature over a period of 10 minutes. The reaction was monitored by TLC. The crude product obtained upon evaporation of the volatiles was purified by silica gel (230-400) column chromatography (3% methanol in dichloromethane) to obtain compound E.

Step 5

[0154] To a stirred solution of compound E (1.0 eq) and 1,3-dimethyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole (1.3 eq) in dioxane : water (6 mL, 30 V) were added potassium carbonate (2.5 eq) and $\text{PdCl}_2(\text{dppf})\text{DCM}$ (0.1 eq) under room temperature. The resulting reaction mass was stirred at 90 °C over a period of 6 hours. The reaction was monitored by TLC. The reaction mass was diluted with ethyl acetate (200 mL) and filtered through celite pad. The organic layer was washed with water (100 mL), brine (50 mL), dried over anhydrous sodium sulphate and concentrated. The crude product obtained was purified by silica gel (230-400) column chromatography (6% methanol in dichloromethane) to obtain a

compound of formula (Ie).


[0155] The compounds of Examples 1 to 7 were synthesized by following the General Procedure 1, using the appropriate amines of formula (III). The analytical data of the compounds of Examples 1 to 7 are represented in **Table 2**.


Table 2

Ex.	Analytical Data
1	¹ H-NMR (CDCl ₃ , 400 MHz): δ 8.61 (d, 2H), 7.91 (s, 1H), 7.69 (d, 1H), 7.45 (d, 1H), 7.32 (d, 1H), 7.27 (s, 1H), 6.31 (bs, 1H), 5.74 (s, 1H), 4.59 (d, 2H), 4.05 (s, 3H), 2.60 (s, 3H), 2.55 (s, 3H), 2.35 (s, 3H), LCMS: 398.3 [M+H], HPLC purity: 99.25%
2	¹ H-NMR (CDCl ₃ , 400 MHz): δ 8.56 (d, 1H), 8.32 (s, 1H), 8.16 (d, 1H), 7.86 (d, 1H), 7.69 (d, 1H), 7.62 (d, 1H), 7.45 (d, 1H), 7.13 (d, 1H), 5.91 (s, 1H), 4.57 (d, 2H), 4.05 (s, 3H), 2.60 (s, 3H), 2.57 (s, 3H), 2.55 (s, 3H), 2.37 (s, 3H), LCMS: 412.3 [M+H], HPLC purity: 99.98%
3	¹ H-NMR (CDCl ₃ , 400 MHz): δ 7.90(s, 1H), 7.70 (d, 1H), 7.45 (d, 1H), 7.32 (m, 4 H), 6.10 (bs, 1H), 5.81 (s, 1H), 4.52 (d, 2H), 4.05 (s, 3H), 2.60 (s, 3H), 2.53 (s, 3H), 2.37 (s, 3H), LCMS: 431.6 [M+H], HPLC purity: 99.67%
4	¹ H-NMR (CDCl ₃ , 400 MHz): δ 8.20 (d, 1H), 7.89 (s, 1H), 7.67 (d, 1H), 7.62 (d, 1H), 7.44 (d, 1H), 6.76 (d, 1H), 6.31 (s, 1H), 5.90 (s, 1H), 4.47 (d, 2H), 4.05 (s, 3H), 3.95 (s, 3H), 2.61 (s, 3H), 2.52 (s, 3H), 2.39 (s, 3H), LCMS: 428.6 [M+H], HPLC purity: 99.23 %
5	¹ H-NMR (CDCl ₃ , 400 MHz): δ 7.89 (s, 1H), 7.68 (d, 1H), 7.46 (d, 1H), 7.27 (d, 1H), 7.10 (d, 1H), 7.00 (d, 1H) 6.41 (bs, 1H), 5.99 (s, 1H), 4.72 (d, 2H), 4.05 (s, 3H), 2.61 (s, 3H), 2.54 (s, 3H), 2.41 (s, 3H), LCMS: 403.6 [M+H], HPLC purity: 97.48%
6	¹ H-NMR (CDCl ₃ , 400 MHz): δ 7.90 (s, 1H), 7.68 (d, 1H), 7.44 (d, 1H), 7.32 (d, 2H), 6.90 (d, 2H), 6.30 (bs, 1H), 5.91 (s, 1H), 4.47 (d, 2H), 4.05 (s, 3H), 3.83 (s, 3H), 2.60 (s, 3H), 2.53 (s, 3H), 2.38 (s, 3H), LCMS: 427.6 [M+H], HPLC purity: 98.49%
7	¹ H-NMR (CDCl ₃ , 400 MHz): δ 8.02 (m, 2H), 7.90 (s, 1H), 7.82 (d, 1H), 7.75 (d, 1H), 7.62 (m, 3H), 5.98 (s, 1H), 4.64 (d, 2H), 3.99 (s, 3H), 3.20 (s, 3H), 2.50 (s, 3H), 2.43 (s, 3H), 2.22 (s, 3H), LCMS: 475.2 [M+H], HPLC purity: 95.44%

General Procedure 2: Synthesis of pyrazolopyrimidine derivatives (Scheme 2)

[0156]





Scheme 2

Step 1

[0157] To a stirred solution of 5-methyl-1H-pyrazol-3-ylamine, F, (7.0 g, 0.0720 mol), and 3-oxobutyric acid ethyl ester (11.26 mL, 0.0804 mol) in dioxane (70 mL, 10 V) was added acetic acid (2.1 mL, 0.3 V) under room temperature. The resulting reaction mass was stirred at room temperature for 16 hours. The reaction was monitored by TLC. After complete consumption of the starting material, the reaction mass was filtered, and the residue obtained was suspended in diethyl ether (70 mL) and filtered. The product was dried under high vacuum to obtain 2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-ol, G, as a white solid (8.2 g, 69.7%)

Step 2

[0158] To a stirred suspension of compound G (4.0 g, 0.0245 mol), in acetonitrile (40 mL, 10 V) was added phosphorous oxy chloride (4.7 mL, 0.049 mol) at room temperature. The resulting reaction mass was stirred at 90 °C over a period of 16 hours. Starting material consumption was monitored by TLC. The reaction mass was added to ice cold water (50 mL), basified with saturated sodium bicarbonate solution, and extracted with ethyl acetate (200 mL *2). The combined organics were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by silica gel (230-400) column chromatography (3% methanol in dichloromethane) to obtain 7-chloro-2,5-dimethylpyrazolo[1,5-a]pyrimidine, H, as an off-white solid (3.0 g, 68%).

Step 3

[0159] To a stirred suspension of compound H (1.5 g, 0.008 mol) in acetonitrile (15 mL, 10 V) was added N-iodo succinamide (1.85 g, 0.008 mol) under ice temperature. The resulting reaction mass was stirred at ice temperature over a period of 10 minutes. The reaction was

monitored by TLC. The crude reaction mass was concentrated and purified by silica gel (230-400) column chromatography (3% methanol in dichloromethane) to obtain 7-chloro-3-iodo-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine, I, as an off-white solid (2.3 g, 92%).

Step 4

[0160] To a stirred solution of compound I (0.6 g, 1.9 mmol) in ethanol (12 mL, 20 V) were added N,N-diisopropyl ethylamine (0.72 mL, 3.9 mmol) and the amine R_ANH₂ (1.3 eq) at RT. The reaction mass was stirred at 70 °C for 16 hours. Starting material consumption was monitored by TLC. After complete evaporation of the volatiles the crude product was diluted with ethyl acetate (200 mL), washed with water (100 mL), dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by silica gel (230-400) column chromatography (3% methanol in dichloromethane) to obtain the compound J.

Step 5

[0161] To a stirred solution of compound J (1.0 eq) and 1,3-dimethyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole (1.3 eq) in dioxane:water (10 mL, 20 V) were added potassium carbonate (2.5 eq) and PdCl₂(dppf)DCM (0.1eq) under room temperature. The resulting reaction mass was stirred at 90 °C over a period of 16 hours. The reaction was monitored by TLC. The reaction mass was diluted with ethyl acetate (200 mL) and filtered through celite pad. The organic layer was washed with water (100 mL), brine (50 mL), dried over anhydrous sodium sulphate and concentrated. The crude product was purified by silica gel (230-400) column chromatography (6% methanol in dichloromethane) to obtain a compound of formula (If).

[0162] The compounds of Examples 8 to 19 were synthesized by following the General Procedure 2, using the appropriate amines of formula (III).

[0163] Analytical data of the compounds of Examples 8 to 19 are represented in Table 3.


Table 3

Ex.	Analytical Data
8	¹ H-NMR (DMSO, 400 MHz): δ 8.52 (m, 3H), 7.85 (s, 1H), 7.75 (d, 1H), 7.59 (d, 1H), 7.37 (d, 2H), 5.96 (s, 1H), 4.65 (d, 2H), 3.97 (s, 3H), 2.56 (s, 3H), 2.50 (s, 3H), 2.31 (s, 3H), LCMS: 398.2 [M+H], HPLC purity: 94.47%
9	¹ H-NMR (DMSO, 400 MHz): δ 8.53 (s, 1H), 8.41 (s, 1H), 7.84 (s, 1H), 7.73 (dd, 2H), 7.59 (d, 1H), 7.21 (d, 1H), 6.02 (s, 1H), 4.58 (d, 2H), 3.97 (s, 3H), 2.54 (s, 3H), 2.49 (s, 3H), 2.43 (s, 3H), 2.34 (s, 3H), LCMS: 412.3 [M+H], HPLC purity: 99.86%
	¹ H-NMR (DMSO, 400 MHz): δ 8.38 (t, 1H), 7.84 (s, 1H), 7.75 (d, 1H), 7.58

Ex.	Analytical Data
10	(d, 1H), 7.35 (d, 2H), 6.90 (d, 2H), 6.00 (s, 1H), 4.52 (d, 2H), 3.97 (s, 3H), 2.54 (s, 3H), 2.50 (s, 3H), 2.32 (s, 3H), LCMS: 427.3 [M+H], HPLC purity: 99.74%
11	¹ H-NMR (DMSO, 400 MHz): δ 8.48 (t, 1H), 7.85 (s, 1H), 7.75 (d, 1H), 7.58 (d, 1H), 7.40 (m, 4 H), 5.99 (s, 1H), 4.60 (d, 2H), 3.97 (s, 3H), 2.55 (s, 3H), 2.52 (s, 3H), 2.32 (s, 3H), LCMS: 431.3 [M+H], HPLC purity: 99.92%
12	¹ H-NMR (CDCl ₃ , 400 MHz): δ 8.00 (s, 1H), 7.94 (d, 1H), 7.87 (d, 1H), 7.70 (dd, 2H), 7.60 (dd, 1H), 7.4 (d, 1H) 6.74 (bs, 1H), 4.72 (d, 2H), 4.03 (s, 3H), 3.08 (s, 3H), 2.60 (s, 3H), 2.58 (s, 3H), 2.45 (s, 3H), LCMS: 475.3 [M+H], HPLC purity: 99.79%
13	¹ H-NMR (CDCl ₃ , 400 MHz): δ 7.85 (m, 3H), 7.69 (d, 1H), 7.51 (d, 2H), 7.41 (d, 1H), 7.15 (br, 1H), 5.80 (s, 1H), 4.86 (s, 2H), 4.70 (d, 2H), 4.04 (s, 3H), 2.61 (s, 3H), 2.57 (s, 3H), 2.51 (s, 3H), LCMS: 476.2 [M+H], HPLC purity: 99.86%
14	¹ H-NMR (CDCl ₃ , 400 MHz): δ 8.21 (d, 1H), 7.87 (s, 1H), 7.73 (d, 1H), 7.63 (d, 1H), 7.40 (d, 1H), 6.79 (d, 2H), 6.52 (s, 1H), 5.86 (s, 1H), 4.54 (d, 2H), 4.02 (s, 3H), 3.96 (s, 3H), 2.60 (s, 3H), 2.57 (s, 3H), 2.51 (s, 3H), LCMS: 428.3 [M+H], HPLC purity: 99.67%
15	¹ H-NMR (CDCl ₃ , 400 MHz): δ 7.87 (s, 1H), 7.72 (d, 1H), 7.40 (d, 1H), 7.30 (d, 1H), 7.11 (d, 1H), 7.02 (d, 1H), 6.67 (bs, 1H), 5.92 (s, 1H), 4.80 (d, 2H), 4.02 (s, 3H), 2.60 (s, 3H), 2.57 (s, 3H), 2.55 (s, 3H), LCMS: 403.0 [M+H], HPLC purity: 99.76%
16	¹ H-NMR (DMSO, 400 MHz): δ 9.71 (s, 1H), 8.41 (t, 1H), 7.85 (s, 1H), 7.75 (d, 1H), 7.58 (d, 1H), 7.38 (d, 2H), 7.17 (d, 2H), 6.00 (s, 1H), 4.54 (d, 2H), 3.97 (s, 3H), 2.96 (s, 3H), 2.54 (s, 3H), 2.32 (s, 3H), LCMS: 490.6 [M+H], HPLC purity: 99.92%
17	¹ H-NMR (DMSO, 400 MHz): δ 8.86 (s, 1H), 8.58 (t, 1H), 8.08 (d, 1H), 7.89 (d, 1H), 7.858 (s, 1H), 7.73 (d, 1H), 7.58 (d, 1H), 6.12 (s, 1H), 4.76 (d, 2H), 3.97 (s, 3H), 2.56 (s, 3H), 2.50 (s, 3H), 2.32 (s, 3H), LCMS: 466.6 [M+H], HPLC purity: 99.40 %
18	¹ H-NMR (DMSO, 400 MHz): δ 8.44 (t, 1H), 7.85 (s, 1H), 7.77 (d, 1H), 7.58 (d, 1H), 7.41 (d, 2H), 7.34 (m, 2H), 7.25 (m, 1H), 5.99 (s, 1H), 4.60 (d, 2H), 3.97 (s, 3H), 2.55 (s, 3H), 2.50 (s, 3H), 2.31 (s, 3H), LCMS: 397.6 [M+H], HPLC purity: 99.80 %
19	¹ H-NMR (DMSO, 400 MHz): δ 8.44 (t, 1H), 7.82 (s, 1H), 7.71 (d, 1H), 7.54 (d, 1H), 7.44 (dd, 12H), 7.14 (m, 2H), 5.99 (s, 1H), 4.56 (d, 2H), 3.974 (s, 3H), 2.50 (s, 3H), 2.47 (s, 3H), 2.30 (s, 3H), LCMS: 415.7 [M+H], HPLC purity: 97.53%

General Procedure 3: Synthesis of pyrazolo triazine derivatives (Scheme 3)

[0164]



Scheme 3

Step 1

[0165] A suspension of 5-methyl-1H-pyrazol-3-ylamine, F, (2.0 g, 0.02 mol) in acetonitrile (50 mL, 25 V) was basified with diisopropylethylamine until the reaction mass showed pH 9-10. To the reaction mixture, ethylacetamidate hydrochloride (3.8 g, 0.03 mol) was added at RT under nitrogen atmosphere and the mixture was stirred for 15 minutes, whereafter the reaction mass was again basified with diisopropylethylamine (pH 9-10). Acetic acid (1.13 mL, 0.02 mol) was added to the suspension and stirred for 16h. The reaction was monitored by TLC. After completion, the reaction mass was diluted with diethyl ether (25 mL), and the solid was filtered and washed with diethyl ether. The filtered solid was dried under high vacuum at 50-55°C to get pure N-(5-methyl-2H-pyrazol-3-yl)-acetamidine, N, (2.4 g, 72%) as a white solid.

Step 2

[0166] To a solution of sodium metal (2.74 g, 0.12 mol) in ethanol (23 mL, 30 V) under nitrogen atmosphere was added N (3.3 g, 0.02 mol) and diethyl carbonate (23 mL, 0.2 mol) at room temperature. The resulting reaction mass was refluxed for 16h. The progress of the reaction was monitored by TLC. After completion, the reaction mass was cooled to room temperature and resultant mass was concentrated under reduced pressure at 50-55 °C to remove ethanol. The crude product obtained upon evaporation of the volatiles were diluted with water and acidified with acetic acid (pH: 4-5). The aqueous layer was extracted with dichloromethane (400 mL*3), the organic layers were combined, dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The solid product was washed with minimum volumes of acetonitrile, filtered and dried to get pure 2,7-dimethyl-3H-pyrazolo[1,5-a][1,3,5]triazin-4-one, L, (1.6 g, 40 %) as an off-white solid.

Step 3

[0167] To a stirred solution of compound L (1.0 g, 0.006 mol) in acetonitrile (10 mL, 10 V) was added N-bromo succinamide (1.3 g, 0.007 mol) under ice temperature. The resulting reaction mass was stirred at ice temperature over a period of 1 hour. The reaction was monitored by TLC. The precipitate formed was filtered through buchner funnel, washed with minimum amount of acetonitrile and dried to obtain 8-bromo-2,7-dimethyl-3H-pyrazolo[1,5-a][1,3,5]triazin-4-one, M, (0.7 g, 50 %) as a white solid.

Step 4

[0168] To a solution of compound M (0.2 g, 0.8 mmol) in toluene (5 mL, 25 V) were added diisopropylethylamine (0.3 mL, 1.6 mmol) and phosphorous oxy chloride (2.0 mL, 0.02 mol) at room temperature. The resulting reaction mass was stirred at reflux temperature for 16 hours. The crude product obtained upon evaporation of the volatiles was stripped with toluene (10 mL*2) and the 8-bromo-4-chloro-2,7-dimethyl-pyrazolo[1,5-a][1,3,5]triazine, N, obtained was taken to next step without further purification and characterization.

Step 5

[0169] The crude compound N (0.2 g, 0.7 mmol), obtained upon evaporation of volatiles, was dissolved in THF (5 mL, 25 V). Diisopropylethylamine (0.3 mL, 1.5 mmol) and the amine $R_A\text{NH}_2$ (1.2 eq) were added at ice temperature, and the resulting reaction mass was stirred at room temperature for 1 hour. The reaction was monitored by TLC. The reaction mass was diluted with dichloromethane (100 mL), washed with water (50 mL *2) and brine solution (50 mL *2). The organic layer was separated, dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by silica gel (230-400) column chromatography (10% ethyl acetate in hexane) to obtain compound O (120 mg, 43%).

Step 6

[0170] To a stirred solution of compound O (1.0 eq) and 1,3-dimethyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole (1.3 eq) in dioxane:water (14 mL, 20 V) were added potassium carbonate (2.5 eq) and $\text{PdCl}_2(\text{dppf})\text{DCM}$ (0.1 eq) at RT. The resulting reaction mass was stirred at 90 °C for 6 hours. The reaction was monitored by TLC. The reaction mass was diluted with ethyl acetate (200 mL) and filtered through celite pad. The organic layer was washed with water (100 mL), brine (50 mL), dried over anhydrous sodium sulphate and concentrated. The crude product was purified by silica gel (230-400) column chromatography (6% methanol in dichloromethane) to obtain a compound of formula (Ig).

[0171] The compounds of Examples 20 to 28 were synthesized by following the General Procedure 3, using the appropriate amines of formula (III). The analytical data are shown in Table 4.

Table 4

Ex.	Analytical Data
20	¹ H-NMR (DMSO, 400 MHz): δ 9.28 (s, 1H), 8.52 (d, 2H), 7.84 (s, 1H), 7.71 (d, 1H), 7.61 (d, 1H), 7.36 (d, 2H), 4.74 (d, 2H), 3.98 (s, 3H), 2.55 (s, 3H), 2.50 (s, 3H), 2.35 (s, 3H), LCMS: 399.3 [M+H], HPLC purity: 98.48%
21	¹ H-NMR (DMSO, 400 MHz): δ 9.14 (s, 1H), 8.41 (s, 1H), 7.82 (s, 1H), 7.70 (d, 1H), 7.60 (d, 1H), 7.32 (d, 2H), 6.90 (d, 2H), 4.63 (d, 2H), 3.97 (s, 3H), 3.97 (s, 3H), 3.71 (s, 3H), 2.54 (s, 3H), 2.50 (s, 3H), 2.35 (s, 3H), LCMS: 428.3 [M+H], HPLC purity: 97.12%
22	¹ H-NMR (DMSO, 400 MHz): δ 9.26 (s, 1H), 8.49 (d, 1H), 7.82 (d, 1H), 7.58 (m, 2H), 7.60 (d, 1H), 7.20 (d, 2H), 4.67 (d, 2H), 3.97 (s, 3H), 2.53 (s, 3H), 2.50 (s, 3H), 2.40 (s, 3H), 2.35 (s, 3H), LCMS: 413.3 [M+H], HPLC purity: 93.78%
23	¹ H-NMR (DMSO, 400 MHz): δ 9.32 (s, 1H), 7.84 (s, 1H), 7.78 (d, 2H), 7.71 (d, 1H), 7.68 (d, 1H), 7.60 (d, 2H), 7.33 (s, 2H), 4.78 (d, 2H), 3.98 (s, 3H), 2.54 (s, 3H), 2.50 (s, 3H), 2.35 (s, 3H), LCMS: 477.4 [M+H], HPLC purity: 99.97%
24	¹ H-NMR (DMSO, 400 MHz): δ 9.26 (t, 1H) 7.83 (s, 1H), 7.69 (d, 1H), 7.61 (d, 1H), 7.40 (m, 4 H), 4.70 (d, 2H), 3.98 (s, 3H), 3.08 (s, 3H), 2.60 (s, 3H), 2.53 (s, 3H), 2.50 (s, 3H), 2.37 (s, 3H), LCMS: 432.7 [M+H], HPLC purity: 99.84%
25	¹ H-NMR (DMSO, 400 MHz): δ 9.34 (t, 1H) 8.02 (s, 1H), 7.84 (d, 2H), 7.75 (d, 1H), 7.69 (d, 4 H), 7.62 (m, 2H), 4.81 (d, 2H), 3.98 (s, 3H), 3.18 (s, 3H), 2.54 (s, 3H), 2.50 (s, 3H), 2.38 (s, 3H), LCMS: 476.6 [M+H], HPLC purity: 94.13%
26	¹ H-NMR (DMSO, 400 MHz): δ 9.68 (bs, 1H) 9.18 (s, 1H), 7.83 (s, 1H), 7.69 (d, 1H), 7.60 (d, 1H), 7.37 (d, 2H), 7.17 (d, 2H), 4.67 (d, 2H), 3.98 (s, 3H), 2.96 (s, 3H), 2.54 (s, 3H), 2.50 (s, 3H), 2.38 (s, 3H), LCMS: 491.9 [M+H], HPLC purity: 99.91%
27	¹ H-NMR (CDCl ₃ , 400 MHz): δ 7.81 (s, 1H), 7.68 (d, 1H), 7.40 (d, 1H), 7.21 (d, 1H), 7.12 (d, 1H), 7.00 (d, 1H), 6.75 (s, 1H), 5.03 (d, 2H), 4.03 (s, 3H), 2.60 (s, 3H), 2.58 (s, 3H), 2.54 (s, 3H), LCMS: 404.4 [M+H], HPLC purity: 99.32%
28	¹ H-NMR (DMSO, 400 MHz): δ 9.19 (s, 1H), 8.18 (t, 1H), 7.82 (s, 1H), 7.78 (d, 1H), 7.69 (d, 1H), 7.60 (d, 1H), 6.79 (d, 1H), 4.63 (d, 2H), 3.97 (s, 3H), 3.81 (s, 3H), 2.52 (s, 3H), 2.50 (s, 3H), 2.41 (s, 3H), LCMS: 429.6 [M+H], HPLC purity: 99.61%

[0172] Amines R_ANH₂ of use to prepare compounds of the invention are commercially available or may be easily synthesized by the person of ordinary skill in the art. The amines used in each one of the Examples 1-28 are indicated in Table 5.

Table 5

Examples	R _A NH ₂
1, 8, 20	pyridin-4-ylmethanamine
2, 9, 22	(6-methylpyridin-3-yl)methanamine
3, 11, 24	(4-chlorophenyl)methanamine
4, 14, 28	(6-methoxypyridin-3-yl)methanamine
5, 15, 27	thiophen-2-ylmethanamine
6, 10, 21	(4-methoxyphenyl)methanamine
7, 12, 25	(3 -(methylsulfonyl)phenyl)methanamine
13, 23	4-(aminomethyl)benzenesulfonamide
16, 26	N-(4-(aminomethyl)phenyl)methanesulfonamide
17	(6-trifluoromethylpyridin-3-yl)methanamine
18	benzylamine
19	(4- fluorophenyl)methanamine

[0173] Compounds of the general formula (Ih) as defined herein above may be prepared e.g. by following the teachings in Maechling S., et al, J. Comb. Chem. 2010, 12, 818-821.

BIOLOGICAL ASSAYS

In vitro assay in mammalian cell culture

[0174] The antiviral activity of compounds of the invention has been evaluated based on the ability of the compounds to prevent virus from causing viral cytopathic effects (CPE) in mammalian cell culture. Incubation time, cell line, cell density and virus titer differed from assay to assay but the general procedure was as follows:

Cells were cultivated on 96-well flat bottom plates to approximately 90 % confluence (20 000-90 000 cells/well) in a suitable media. The titer of the virus was determined by the standard method of tissue culture infective dose (TCID₅₀) on cells. Briefly, cells were infected with 50 µl of virus suspension, and diluted 10-fold in media. The plates were incubated in 37 °C with 5 % CO₂ for 3-7 days and cells were inspected daily for CPE. After determining CPE, plates were stained with Gram's Crystal Violet solution and optical density was read at 540 nm. The highest virus dilution that resulted in > 95 % CPE was used in the assays. Substances at a final concentration of 0.1 nM-1 µM and the virus were added to the cells and incubated for 3-7 days depending on the virus and cell line used. As controls, uninfected cells and cells infected with virus (no substance) were included on each plate. The cells were stained with crystal violet after determining the CPE on infected controls and the optical density was read at 540 nm. The

Ex.	EV6	EV30	EV68	EV71	B1	B2	B3	B4	B5	Polio 1
26	+	++	++	++	+++	++	++	++	nd	+
27	++	++	++	++	4+	4+	+++	4+	nd	++
28	+	++	+	++	+++	++	++	++	nd	+

[0177] In Table 6 the signs have the following meaning:

+	IC ₅₀ < 1 μM
++	IC ₅₀ < 100 nM
+++	IC ₅₀ < 10 nM
4+	IC ₅₀ < 1 nM
5+	IC ₅₀ < 0.1 nM

Time of addition assay

[0178] The assay was performed like the "in vitro assay in mammalian cell culture" described above with the exception that substance was added one hour pre inoculation (-1 h), at inoculation (0 h), and 2 hours (+2 h), 6 hours (+6 h) or 24 hours (+24 h) past inoculation. The virus EV71 was used at high titer for the test. Table 7 shows data for Example 7 and Example 20. The data show that the time of addition of the drug was not crucial and as long the replication was not too quick the compound could inhibit the cytopathogenic effect in an efficient way.

Table 7

Ex.	Conc.	-1 h	0 h	+2 h	+6 h	+24 h
7	100 nM	0.95	0.85	1.00	0.91	0.02
20	100 nM	0.85	0.94	0.95	0.99	0.02

Phosphatidyl inositol kinase inhibition assay

[0179] Inhibition of PI4 kinases was studied using the ADP-Glo™ Kinase Assay which is a luminescent kinase assay that measures ADP formed from a kinase reaction, wherein ADP is converted into ATP, which is converted into light by Ultra-Glo™ Luciferase. The assay is performed in two steps; first, after the kinase reaction, an equal volume of ADP-Glo™ Reagent is added to terminate the kinase reaction and deplete the remaining ATP. In the second step, the Kinase Detection Reagent is added, which simultaneously converts ADP to ATP and allows the newly synthesized ATP to be measured using a coupled luciferase/luciferin reaction. The

luminescent signal produced is proportional to the activity of the kinase. Inhibition of PI3 kinases was studied using the HTRF (homogeneous time-resolved fluorescence) assay, which is a universal method for identifying and characterizing the phosphotransferase activity induced by any ATP/ADP dependent target. The formation of ADP was detected by a specific monoclonal antibody labeled with Eu^{3+} cryptate, and directly correlated with the amount of phosphorylated substrate. **Table 8** shows test results for some compounds of the invention vs. different kinases, expressed as IC_{50} values (in μM).

Table 8

Kinase	Example 2 IC_{50} (μM)	Example 8 IC_{50} (μM)	Example 12 IC_{50} (μM)	Example 20 IC_{50} (μM)
PI4KIII β	0.0015	0.0009	0.0008	0.0012
PI4KIII α	0.2	1.3	0.8	>1*
PI3K β	1.7	1.5	>1*	>1*
PI3K α	>1*	>1*	>1*	>1*
*No inhibition at the highest tested concentration 1 μM				

Pharmacokinetics in male Sprague Dawley Rats

[0180] Overnight fasted animals were administered with the test compounds in recommended vehicle 0.4% (v/v) Tween 80 + 2% (v/v) Glycerol and 15% w/v HP β CD by oral route with a dose of 50 mg/kg body weight at dose volume of 10 mL/kg bw. Under mild isoflurane anesthesia, blood samples were collected into pre-labeled tubes containing anticoagulant (K_2EDTA - 2 mg/mL blood) during the next 24 hours post dose. Collected blood samples were centrifuged at 4000 rpm, 4°C for 10 minutes and plasma was separated and stored at -80°C until analysis. The analysis showed that the compounds of the invention are orally available with good to excellent bioavailability. Test data are shown in **Table 9** and in **Figure 2**.

Table 9

Parameter	Ex. 1	Ex. 2	Ex. 8	Ex. 12	Ex. 13	Ex. 20
Dose (mg/kg bw)	50.00	50.00	50.00	50.00	50.00	50.00
C_{max} ($\mu\text{g/mL}$)	3.9 $\pm$ 0.4	4.8 $\pm$ 0.8	12.9 $\pm$ 0.7	1.9 $\pm$ 0.1	5.9 $\pm$ 0.9	8.0 $\pm$ 1.5
T_{max} (h)	1.7 $\pm$ 0.6	1.7 $\pm$ 0.6	1.7 $\pm$ 0.6	5.3 $\pm$ 2.3	2 $\pm$ 0	2 $\pm$ 0
AUC_{last} (h $\cdot\mu\text{g/mL}$)	22.2 $\pm$ 2.1	58.6 $\pm$ 9.9	184.7 $\pm$ 13.3	30.0 $\pm$ 8.2	62.1 $\pm$ 10.9	109.8 $\pm$ 8.3
AUC_{inf} (h $\cdot\mu\text{g/mL}$)	31.8 $\pm$ 8.0	64.1 $\pm$ 7.0	196.9 $\pm$ 27.1	73.3 $\pm$ 46.9	76.1 $\pm$ 26.8	115.0 $\pm$ 9.4
$\text{AUC}_{\text{extrap}}$ (%)	27.8 $\pm$ 14.8	8.8 $\pm$ 7.1	5.7 $\pm$ 6.1	49.4 $\pm$ 24.5	14.5 $\pm$ 17.1	5.1 $\pm$ 4.9
$\text{T}_{1/2}$ (h)	4.3 $\pm$ 2.0	6.6 $\pm$ 2.4	5.4 $\pm$ 2.5	27.6 $\pm$ 16.8	8.2 $\pm$ 5.4	5.0 $\pm$ 2.3

Parameter	Ex. 1	Ex. 2	Ex. 8	Ex. 12	Ex. 13	Ex. 20
MRT _{last} (h)	3.4±0.2	6.9±0.8	6.8±0.8	10.3±1.2	7.5±1.4	6.8±0.9

Metabolic stability in human and rat liver microsomes

[0181] Metabolic stability was studied using human (HLM) or rat (RLM) liver microsomes. The final composition of the assay included 5 µM of test item and reference item (Diclofenac or Imipramine) prepared from DMSO stock, so that the final concentration of DMSO was 0.1%, 0.125 mg/mL microsomal protein and cofactors (5.0 mM G-6-P, 0.06 U/mL G-6-PDH, 2.0 mM MgCl₂, 1.0 mM NADP⁺). Test and reference items were incubated with human or rat liver microsomes with or without cofactors. The reaction mixture (100 µL) was removed at specified time periods and the reaction was stopped by addition of stop solution. The samples were extracted in presence of internal standard and were analyzed using LC-MS/MS. The percent of the test/reference item remaining after a specified incubation period was calculated with respect to the peak area ratio at time 0 min. Results are shown in **Table 10**.

Human and rat plasma protein binding by rapid equilibrium dialysis method

[0182] Plasma protein binding study was performed by using a Rapid Equilibrium Dialysis (RED) device containing dialysis membrane with a molecular weight cut-off of 8,000 Daltons. Each dialysis insert contains two chambers. The red chamber was for the plasma while the white chamber was for the buffer. The human and rat plasma (pH adjusted to 7.40) samples of test items and reference items (Warfarin and Propranolol) were prepared at a required test concentration of 5 µM using 5 mM DMSO stocks (final DMSO concentration was 0.1%). 300 µL of plasma sample was added into the sample chamber. 500 µL of buffer was added into the buffer chamber. After sealing the RED device with an adhesive film, incubation was done at 37 °C with shaking at 300 rpm for 4 h. Following incubation, an aliquot of 50 µL was removed from each well (plasma and buffer side) and diluted with equal volume of opposite matrix to nullify the matrix effect. The specimens were subjected to sample extraction in presence of internal standard by liquid-liquid extraction / protein precipitation method. After extraction, the samples were transferred into labeled auto sampler vials and submitted to LC-MS/MS analysis. Results are shown in **Table 10**.

Table 10

Ex.	Remaining after 1 h, HLM	Remaining after 1 h, RLM	t _{1/2} HLM with cofactors	Plasma protein binding, human	Plasma protein binding, rat
1	90%	88%	>120 min	98.4%	97.0%
7	75%	94%	>120 min	99.5%	99.4%

Ex.	Remaining after 1 h, HLM	Remaining after 1 h, RLM	t1/2 HLM with cofactors	Plasma protein binding, human	Plasma protein binding, rat
8	86%	90%	>120 min	97.3%	97.6%
12	84%	71%	>120 min	99.0%	98.5%
20	78%	96%	>120 min	9.4%	96.9%

7 days toxicity studies in rats

[0183] Based on previous toxicity tests with analogs and pharmacokinetic data, repeated dose toxicity and toxicokinetic studies were conducted to generate information on the toxic characteristics of some representative compounds of the invention, viz. Example 8 and Example 12, respectively, when administered orally by gavage to Sprague Dawley rats for a period of 7 consecutive days. The study plan for the studies was by current ICH guidelines for 7 days toxicity studies and the No Observed Adverse Effect Level (NOAEL) of Example 8 and Example 12 was determined as 60 mg/kg body weight/day and 50 mg/kg bodyweight/day respectively when administered once daily orally to Sprague Dawley rats for 7 consecutive days under the tested dose levels and experimental conditions employed.

CVB3-induced pancreatitis mouse model

[0184] Compounds of the present invention were studied in a CVB3 induced pancreatitis mouse model as described by van der Schaar et al (Antimicrob. Agents Chemother. 2013, 57(10):4971-4981). Animals (SJL mice) were infected intraperitoneally with 0.3 ml Coxsackie B3 (Nancy strain) virus (log TCID₅₀ = 8). The animals were treated 2 h pre-infection and then once daily for 3 days. The animals were euthanized and organs were collected for pancreatitis evaluation by histopathology and for virus titer determination by immunohistochemistry and polymerase chain reaction (PCR). Pancreata were obtained from infected and uninfected control animals and from animals treated with 4 different dosages of Example 8, and HE-stained slides of the organs were prepared, studied and scored for signs of inflammation and necrosis on a scale from 0 to 3, as follows: 0= no abnormalities. 1= slight inflammation and/or single cell foci in exocrine pancreas. 2=moderate inflammation and/or several foci with necrosis in exocrine pancreas. 3= severe inflammation and/or large areas of necrosis in exocrine pancreas (**Figure 3**). The virus titer in the organs was determined by immunohistochemistry using the Dako 5-D8/1 monoclonal mouse antibody and the titer was scored on a scale from 0 to 4, where 0 indicates no infection and 4 corresponds to the highest determined virus titer (**Figure 4**). The Ct values from PCR detection of virus titers were determined (**Figure 5**). The higher the Ct value is, the lower is the virus titer. The data show a very good dose-response. Corresponding studies were also performed on Examples 2, 8 and 20 at a dosage of 50 mg/kg/day and pancreatitis

scoring and Ct values were determined (Figure 6).

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.


Patent documents cited in the description

- [US6313124B1 \[0002\]](#)
- [WO2010086040A \[0002\]](#)
- [WO2015110491A \[0002\]](#)
- [WO2013128029A \[0002\]](#)
- [WO2010103486A \[0002\]](#)
- [WO2016206999A \[0002\]](#)

Non-patent literature cited in the description

- MAYO et al. Adv. Synth. Catal., 2003, vol. 345, 620-624 [0002]
- TELLEW et al. Bioorg. Med. Chem. Lett., 2010, vol. 20, 7259-7264 [0002]
- CHEN et al. Bioorg. Med. Chem. Lett., 2004, vol. 14, 3669-3673 [0002]
- LABROLI et al. Bioorg. Med. Chem. Lett., 2011, vol. 21, 471-474 [0002]
- GRIFFITH et al. Bioorg. Med. Chem. Lett., 2011, vol. 21, 2641-2645 [0002]
- GILLIGAN et al. J. Med. Chem., 2009, vol. 52, 3073-3083 [0002] [0002]
- CATALANO et al. Tetrahedron Lett., 2015, vol. 56, 6077-6079 [0002]
- BIANCO et al. PLoS Pathogens, 2012, vol. 8, 31-17 [0002] [0003]
- LAMARCHE et al. Antimicrob. Agents and Chemother., 2012, vol. 56, 105149-5156 [0002] [0003]
- YANG et al. J. Biol. Chem., 2012, vol. 287, 118547-8467 [0002]
- GUDMUNDSSON et al. Bioorg. Med. Chem. Lett., 2009, vol. 19, 5689-5692 [0002]
- HWANG et al. Bioorg. Med. Chem. Lett., 2012, vol. 22, 7297-7301 [0002]
- J. Pharm. Exp. Ther., 2010, vol. 335, 1103-113 [0002]
- MEJDROVA et al. J. Med. Chem., 2015, vol. 58, 93767-3793 [0002]
- MEJDROVA et al. J. Med. Chem., 2017, vol. 60, 1100-118 [0002]
- KUSAKABE J. Med. Chem., 2015, vol. 58, 1760-1775 [0003]

- MCLEOD et al.ACS Med. Chem. Lett., 2013, vol. 4, 7585-589 [0003]
- VAN DER SCHAAR et al.Antimicrobial Agents Chemother., 2013, vol. 57, 104971-4981 [0003]
- DÉCOR et al.Bioorg. Med. Chem. Lett., 2013, vol. 23, 3841-7 [0003] [0004]
- SALA et al.Bioorg. Med. Chem. Lett., 2016, vol. 26, 112706-12 [0004]
- KARANASIOS et al.Autophagy at the cell, tissue and organismal levelSpringer20160000 [0005]
- LAI et al.Viruses, 2016, vol. 8, 321-13 [0005]
- SRIDHAR et al.EMBO J., 2013, vol. 32, 324-339 [0005]
- POLAJNAR et al.J. Cell. Mol. Med., 2014, vol. 9, 181705-1711 [0005]
- LEVINE et al.Cell, 2008, vol. 132, 127-42 [0005]
- BARLOW et al.DNA Cell. Biol, 2015, vol. 34, 4252-260 [0005]
- Remington's Pharmaceutical SciencesMack Publishing Company [0135]
- MAECHLING S. et al.J. Comb. Chem., 2010, vol. 12, 818-821 [0173]
- VAN DER SCHAAR et al.Antimicrob. Agents Chemother., 2013, vol. 57, 104971-4981 [0184]

Patentkrav**1.** Forbindelse af formel (I)

eller et farmaceutisk acceptabelt salt deraf, hvor

5 X er CH eller N;

Y er N og Z er C; eller Y er C og Z er N;

den 5-leddede ring, som indeholder N, Y og Z er en heteroaromatisk ring;

ring A er phenyl eller 5- eller 6-leddet heteroaryl, som har et eller flere heteroatomer uafhængigt valgt fra N, O og S;

10 m er 0, 1 eller 2;

hvert R₁ er uafhængigt valgt fra halogen, C1-C6 alkyl, R₂O, R₃S(O)₂, R₄S(O)₂N(R₅), R₆R₇NC(O), R₈C(O)N(R₉), R₁₀C(O), R₁₁R₁₂N, og R₁₃R₁₄NS(O)₂, og

15 når m er 2, to R₁ fastgjort til tilstødende atomer af ring A, sammen med atomerne til hvilke de er fastgjort, kan danne en 5- eller 6-leddet heterocyklisk eller carbocyklisk ring;

hver ene af R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, og R₁₃ er uafhængigt valgt fra H og C1-C6 alkyl;

R₁₄ er valgt fra H, C1-C6 alkyl, R₁₅C(O), og R₁₆OC(O);

20 R₁₅ og R₁₆ er uafhængigt valgt fra H og C1-C6 alkyl; og

ethvert alkyl er eventuelt substitueret af en eller flere halogen.

2. Forbindelsen eller det farmaceutisk acceptable salt ifølge krav 1, hvor X er CH.

25 **3.** Forbindelsen eller det farmaceutisk acceptable salt ifølge krav 1 eller 2, hvor Y er N og Z er C.


4. Forbindelsen eller det farmaceutisk acceptable salt ifølge krav 1 eller 2, hvor Y er C og Z er N.

5. Forbindelsen eller det farmaceutisk acceptable salt ifølge krav 1 eller 3, hvor X er N.


6. Forbindelsen eller det farmaceutisk acceptable salt ifølge et hvilket som helst af kravene 1 til 5, hvor ring A er 5- eller 6-leddet heteroaryl.

7. Forbindelsen eller det farmaceutisk acceptable salt ifølge et hvilket som helst af kravene 1 til 5, hvor ring A er phenyl eller 6-leddet heteroaryl.

8. Forbindelsen eller det farmaceutisk acceptable salt ifølge krav 7, hvor delen



er en del af formel (IIa)



hvor W_1 og W_2 er uafhængigt valgt fra N, CH og CR_1 .

9. Forbindelsen eller det farmaceutisk acceptable salt ifølge krav 8, hvor W_1 er N og W_2 er CR_1 ; eller W_1 er CH og W_2 er CR_1 ; eller W_1 er CH og W_2 er N.

10. Forbindelsen eller det farmaceutisk acceptable salt ifølge krav 9, hvor W_1 er N og W_2 er CR_1 ; eller W_1 er CH og W_2 er N.

11. Forbindelse ifølge krav 1, valgt fra

3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amin,

3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-((6-methylpyridin-3-yl)methyl)pyrazolo[1,5-a]pyrimidin-7-amin,

- 3-(1,3-dimethyl-1H-indazol-5-yl)-N-(4-methoxybenzyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amin,
 N-(4-chlorbenzyl)-3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amin,
- 5 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-(4-(methylsulfonyl)benzyl)pyrazolo[1,5-a]pyrimidin-7-amin,
 4-(((3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)amino)methyl)benzensulfonamid,
- 10 3-(1,3-dimethyl-1H-indazol-5-yl)-N-((6-methoxypyridin-3-yl)methyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amin,
 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-(thiophen-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amin,
 N-(4-(((3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)amino)methyl)phenyl)methansulfonamid,
- 15 8-(1,3-dimethyl-1H-indazol-5-yl)-2,7-dimethyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amin,
 8-(1,3-dimethyl-1H-indazol-5-yl)-N-(4-methoxybenzyl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amin,
- 20 8-(1,3-dimethyl-1H-indazol-5-yl)-2,7-dimethyl-N-((6-methylpyridin-3-yl)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amin,
 4-(((8-(1,3-dimethyl-1H-indazol-5-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)benzensulfonamid,
 N-(4-chlorbenzyl)-8-(1,3-dimethyl-1H-indazol-5-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amin,
- 25 8-(1,3-dimethyl-1H-indazol-5-yl)-2,7-dimethyl-N-(4-(methylsulfonyl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amin,
 N-(4-(((8-(1,3-dimethyl-1H-indazol-5-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)methansulfonamid,
- 30 8-(1,3-dimethyl-1H-indazol-5-yl)-2,7-dimethyl-N-(thiophen-2-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amin,

- 8-(1,3-dimethyl-1H-indazol-5-yl)-N-((6-methoxypyridin-3-yl)methyl)-2,7-dimethylpyrazolo [1,5-a][1,3,5]triazin-4-amin,
- 3-(1,3-dimethyl-1H-indazol-5-yl)-2,6-dimethyl-N-(pyridin-4-ylmethyl)imidazo[1,2-b]pyridazin-8-amin,
- 5 3-(1,3-dimethyl-1H-indazol-5-yl)-2,6-dimethyl-N-((6-methylpyridin-3-yl)methyl)imidazo[1,2-b]pyridazin-8-amin,
- N-(4-chlorbenzyl)-3-(1,3-dimethyl-1H-indazol-5-yl)-2,6-dimethylimidazo[1,2-b]pyridazin-8-amin,
- 10 3-(1,3-dimethyl-1H-indazol-5-yl)-N-((6-methoxypyridin-3-yl)methyl)-2,6-dimethylimidazo [1,2-b]pyridazin-8-amin,
- 3-(1,3-dimethyl-1H-indazol-5-yl)-2,6-dimethyl-N-(thiophen-2-ylmethyl)imidazo[1,2-b]pyridazin-8-amin,
- 3-(1,3-dimethyl-1H-indazol-5-yl)-N-(4-methoxybenzyl)-2,6-dimethylimidazo[1,2-b]pyridazin-8-amin,
- 15 3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethyl-N-((6-trifluormethylpyridin-3-yl)methyl)pyrazolo[1,5-a]pyrimidin-7-amin,
- N-(benzyl)-3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amin,
- 20 N-(4-fluorbenzyl)-3-(1,3-dimethyl-1H-indazol-5-yl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amin, og
- 3-(1,3-dimethyl-1H-indazol-5-yl)-2,6-dimethyl-N-(4-(methylsulfonyl)benzyl)imidazo[1,2-b]pyridazin-8-amin;

eller et farmaceutisk acceptabelt salt deraf.

- 25 **12.** Forbindelse eller farmaceutisk acceptabelt salt ifølge et hvilket som helst af kravene 1 til 11, til anvendelse i terapi.

- 13.** Farmaceutisk sammensætning omfattende en forbindelse eller et farmaceutisk acceptabelt salt ifølge et hvilket som helst af kravene 1 til 11, og
- 30 eventuelt en farmaceutisk acceptabel excipiens.

14. Forbindelse eller farmaceutisk acceptabelt salt ifølge et hvilket som helst af kravene 1 til 11, til anvendelse i behandlingen af en lidelse valgt fra pancreatitis, poliomyelitis, encefalitis, meningitis, sepsis, kræft, såsom brystkræft, prostatakkræft, kræft i æggestokkene og kolorektal kræft, lammelse, 5 hjertesygdomme, såsom myocarditis, diabetes, forkølelse, hånd-, fod- og mundsygdom, herpangina, pleurodynia, diarré, mucocutane læsioner, åndedrætssygdom, konjunktivitis, myositis, kronisk træthedssyndrom, neuropsykiatriske sygdomme, neurodegenerative sygdomme såsom multipel sklerose, Parkinsons sygdom, amyotrofisk lateral sklerose, Alzheimers sygdom og 10 Huntingtons sygdom og inflammatoriske tilstande.

15. Forbindelse eller farmaceutisk acceptabelt salt ifølge et hvilket som helst af kravene 1 til 11, til anvendelse i behandlingen af en viral infektion.

DRAWINGS




Figure 1




Figure 2

Figure 3




Figure 4





Figure 5






Figure 6